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Eksem hos barn og ungdom 
PACT og Ung-HUNT  
 
Atopisk eksem er en av de vanligst forekommende inflammatoriske hudlidelser i den 
generelle befolkning, og opp mot 25% av alle barn i den vestlige verden er rammet. 
Sykdommen medfører betydelig reduksjon i livskvalitet, og utgjør også en stor sosio-
økonomisk belastning for barna og deres familier. Epidemiologisk studier omkring atopisk 
eksem er viktig for å undersøke risikofaktorer for utvikling av sykdom, samt studere effekten 
av spesifikke intervensjonstiltak. Atopisk eksem forårsakes av en kompleks interaksjon 
mellom gener (arv) og miljø, og er assosiert med andre allergiske lidelser som astma og 
høysnue. Den atopiske marsjen er et begrep som brukes for å beskrive den gradvise 
utviklingen av allergiske lidelser, eksem starter i tidlig barndom og etterfølges så av astma og 
høysnue noe senere. I denne avhandlingen har vi brukt data fra to store befolknings-
undersøkelser i Midt-Norge, The Prevention of Allergy among Children in Trondheim 
(PACT) study og Ung-HUNT 1. Vi har studert forekomst, alvorlighetsgrad, arv og den 
atopiske marsj hos barn (PACT) og assosiasjon mellom eksem og symptomer relatert til 
mental helse hos ungdommer (Ung-HUNT1). 
I den første studien ble et tilfeldig utvalg av 390 2-åringer tilhørende kontroll kohorten i 
PACT innkalt til klinisk undersøkelse. Vi fant at forekomsten av eksem i denne aldersgruppen 
var relativt høy, 16.5%, men mer enn to tredjedeler av barna hadde lett/mild grad av eksem. 
Data fra både kontroll kohorten og intervensjonskohorten i PACT ble brukt for å studere om 
eksem rapportert ved alder 2 år følger en maternell eller en paternell nedarvingslinje. 
Informasjon innhentet ved alder 6 uker ble sammenlignet med informasjon innhentet ved 
alder 1 år. Eksem hos både mor og far var assosiert med eksem hos barnet, og vi fant ingen 
holdepunkt for at arvegangen fulgte kun en av foreldrene. Eksem hos søsken var imidlertid 
kun assosiert med eksem når informasjonen ble rapportert ved alder 1 år.  
Vi brukte data fra kontroll kohorten i PACT for å studere den atopiske marsj. Helsedata ble 
rapportert da barnet var 2 og 6 år. På tross av at de fleste tilfeller av eksem i en generell 
populasjon er milde, fant vi at barn med eksem ved alder 2 år hadde en økt risiko for å 
rapportere astma ved alder 6 år sammenlignet med barn uten eksem ved alder 2 år.   
I den siste studien brukte vi data fra Ung-HUNT1. Vi studerte symptomer relatert til mental 
helse hos ungdommer med eksem. Vi sammenlignet eksem med andre kroniske plager som 
hodepine og nakke/skulder smerter, og fant at alle var assosiert med økt risiko for mental 
”distress”.  For ungdommer med eksem var imidlertid denne assosiasjonen sterkere for gutter 
enn for jenter.  
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INTRODUCTION 
One of the first individuals described with symptoms 
resembling atopic dermatitis/eczema was emperor 
Augustus (63 BC-AD 14).1 According to the historian 
Suetonius (70-130 AD), he suffered from “itchy dry 
patches of the skin, and also from seasonal respiratory 
symptoms”. The word “eczema” comes from the 
Greek word “εκξεμα” meaning “to boil out”.2 Aëtius 
of Amida, a writer and physician who lived some 
1500 years ago was the first one known to use the 
word. It is said to have been the name given by 
ancient physicians to any fiery pustule on the skin. 
Since then, several descriptions have been given to    
the skin condition we today recognize as eczema. In 1844 Ferdinand Ritter von Hebra, 
professor of dermatology in Vienna, described a condition  with chronic, recurrent, intensely 
pruritic papules and nodules located to the limbs and trunk and this became synonymous to 
the most severe types of eczema among children and adults (prurigo ferox).3  Another 
milestone in the attempt of describing atopic dermatitis/eczema came in 1892 by Ernest Henri 
Besnier. He described a disease featuring chronic relapsing lichenified lesions with 
involvement of the flexures.4 In many European countries the term prurigo Besnier is still 
used to describe atopic dermatitis/eczema. The word “atopy” is derived from the Greek word 
“ατοπια”, meaning “out of place” or “unusual”. In order to emphasize the association of 
eczema to allergic rhinitis and asthma, Wise and Sulzberger introduced the term “atopic 
dermatitis” in 1933.5 Since then, this term has been prevailing in the dermatological 
community.  
Figure 1. Bust of emperor Augustus. 
From Uffizi Gallery, Florenze, Italy. 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
BACKGROUND 
General 
Epidemiology is defined as “the study of how diseases are distributed in populations and the 
factors that influence or determine this distribution”.6 A major role of epidemiology is to 
describe and provide clues to changes that take place over time regarding health problems 
presenting in the community.7 Atopic dermatitis is one of the most common inflammatory 
skin diseases in the general population. It has great impact on patients and their families’ 
quality of life and is a major socioeconomic burden.8 Epidemiologic studies on atopic 
dermatitis is helpful not only in defining disease burden in a population, but also in 
investigating risk factors for disease and serve as a basis for the development of specific 
prevention strategies.  
 
Eczema and other allergy related diseases – definitions and key concepts 
The Skin 
The skin comprises three layers; the subcutis, the dermis and the epidermis.  
The subcutis contains subcutaneous fat as well as loosely woven connective tissue. It 
functions as an energy reservoir and also as insulation. In the dermis, the connective tissue is 
more compact and elastic. Dermis also contains sweat-glands, hair follicles and certain cells 
such as T-cells, dendritic cells, macrophages and mast cells.   
The epidermis is the outer layer of the skin.  Epidermis acts as a physical barrier against 
harmful irritants and organisms, and prevents water-loss from the body. It consists of a 
stratified squamous epithelium with no blood vessels, and a basal membrane separates it from 
the dermis. The main cell-type is the keratinocyte. They accumulate keratin and achieve a flat 
appearance as they move outward and finally rub off. Other cell-types in the epidermis are 
melanocytes, Langerhans cells and Merkel cells. The upper layer of the epidermis, the stratum 
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corneum, forms the actual barrier. Disturbance of the pH of the stratum corneum followed by 
changes in skin ceramides as well as alterations in expression of enzymes involved in 
epidermal adhesion structures can contribute to the breakdown of the epidermal barrier in 
patients with atopic dermatitis/eczema.9-11 Also located in the epidermis is the protein 
filaggrin (FLG). This protein is essential in maintaining the skin-barrier and preventing trans-
epidermal water-loss.12, 13  
 
Nomenclature 
Over the years, more than 20 different names have been used to describe the disease we today 
refer to as atopic dermatitis /atopic eczema. The disease includes several phenotypes with 
certain clinical characteristics in common, and the terms dermatitis/eczema are often used 
interchangeably. Allergen-specific immunoglobulin E (IgE) sensitization is clearly associated 
with atopic dermatitis. Patients with atopic dermatitis are, however, truly atopic in the sense 
of IgE sensitized in only about one third of the cases.14 This led The European Academy of 
Allergology and Clinical Immunology (EAACI) nomenclature task force to propose a new 
diagnostic classification of allergic skin disorders in 2001.15, 16 EAACI defines 
hypersensitivity as “objectively reproducible symptoms or signs, initiated by exposure to a 
defined stimulus at a dose tolerated by normal subjects”. Allergy is “a hypersensitivity 
reaction initiated by immunologic mechanisms” and atopy is “a personal or familial tendency 
to produce IgE antibodies in response to low doses of allergens, usually proteins, and as a 
consequence develop typical symptoms such as asthma, rhino-conjunctivitis or 
eczema/dermatitis”.16 Instead of atopic dermatitis/eczema, the task force proposed the term 
atopic eczema/dermatitis syndrome (AEDS). In order to create a globally acceptable 
nomenclature for allergic diseases, the World Allergy Organization (WAO) revised the 
EAACI Nomenclature Position Statement in 2003.17 This resulted in “dermatitis” as an 
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umbrella term for a local inflammation in the skin. In addition, the term “eczema” replaced 
AEDS. (Fig.2) 
 
    
 
 
 
 
When used as recommended by WAO, eczema is used when sensitization status is unknown. 
Atopic eczema is used when sensitization is positive. 
 
Point of clarification 
In the four papers included in this thesis, both “atopic dermatitis” and “eczema” has been 
used. In paper I and IV, the term atopic dermatitis is used in the WAO meaning “eczema”.  
When referring to other studies, atopic eczema/dermatitis and eczema are used in line with 
how the authors have used the term. 
 
 
 
 
Figure 2. Nomenclature for dermatitis (Reprinted from J Allergy Clin Immunology, Vol 
113(5), May 2004, Johansson SG et al. Revised nomenclature for allergy for global use: 
Report of the Nomenclature Review Committee of the World Allergy Organization, October 
2003, pp832-6. Copyright (2004), with permission from Elsevier.) 
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Eczema 
Epidemiology 
Early epidemiologic questionnaire-based studies on eczema reported prevalence estimates in 
the range from 1.1% to 3.1%.18 Studies conducted in the 1980s and 1990s revealed prevalence 
estimates up to 26%.19 Also within Norway, the reported prevalence has varied between 25%-
26% in the north and southwest, and 8% in Oslo.19-21 Absences of unambiguous diagnostic 
criteria, use of different prevalence measurements and studies of different age-groups have, 
however, made comparison between studies challenging.    
To attain a better global understanding of the allergic and non-allergic diseases, the 
International Study of Asthma and Allergy in Childhood (ISAAC) Steering Committee was 
established in 1991. As of today, more than 100 countries and about 2 million children have 
participated in this comprehensive epidemiologic study. ISAAC has conducted a systematic 
comparison between children 13-14 years of age and children 6-7 years of age in different 
countries. The first results were published in 1998.22 Children self-reported through one-page 
questionnaires and the variations in prevalence of the different allergic diseases were striking 
throughout the world. Some of the highest prevalence of eczema was found in northern 
Europe (Finland, Sweden and United Kingdom). Three different phases of the ISAAC has 
been completed,23, 24 and so far the findings suggest that the increase in prevalence has little 
to do with allergy.23  
In a summary of studies measuring prevalence of eczema from 1990 to 2008, 48 different 
studies were identified, of which 23 included children under the age of 6.25 The point 
prevalence varied from 1.0% in South-Africa (age 3-11)26 to 24% in Japan (age 5-6).27 The 
period prevalence varied from 1.8% in Ethiopia (age 1-5)28 to 16.5% in the UK (age 1-5).29 
The highest cumulative incidence where found among 3 year-olds in Denmark, 44.0%.30 
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Clinical features 
Eczema is a chronic, relapsing, inflammatory skin disease and the main symptoms are dry 
skin and pruritus.31  In addition, there are skin lesions on typical locations such as flexures of 
knee and elbow, neck and face. These lesions are characterized by poorly defined erythema 
with edema, vesicles and oozing in the acute stage and skin thickening (lichenification) in the 
chronic stage. Typical location of the eczema varies with age.32 In infancy (0-1 year), the 
eczema is often localized to the cheeks and the scalp in addition to the trunk and the extensor 
surface of the extremities. During childhood (1-4 years) the eczema can still be located on the 
extensor side of the extremities, but also on the flexural areas. In addition, the mouth, eyelids, 
neck and hands might be involved. Children from 4-16 years usually have eczema on the 
flexural areas, as well as on their hands and feet. Adults (over 16 years) tend to have 
involvement of their face, upper body, flexural areas and hands.    
 
Etiology - Genetics  
It is a well-established fact that atopic dermatitis is caused by an interaction between genes 
and environmental factors. The genetic component is demonstrated in twin studies, were the 
concordance rate for monozygotic twins are higher than among dizygotic twins.33  
 Genetic studies have identified several possible eczema loci located on chromosomes 1q21, 
3q21, 3p26 and 17q25.34-40 In addition, other loci such as 20p, 16q, 4p, 18q, 13q and 15q   
have been mapped and showed suggestive evidence of linkage. The region of highest linkage 
was identified on chromosome 1q21. Recently, a genome-wide association meta-analysis 
including 16 different European cohorts identified three new risk loci for atopic dermatitis.41 
In addition to linkage approaches, several candidate genes have also been of interest in 
studying atopic dermatitis. In the last years the gene encoding filaggrin (FLG) have been 
investigated in several studies.12, 42, 43     
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FLG is a large filament aggregating protein located in the granular layer of the epidermis. Its 
precursor is profilaggrin, and when cleaved every protein of profilaggrin forms 10-12 copies 
of FLG.12 FLG is essential in building the keratin filaments into tight bundles, which lead the 
cells to collapse into flattened squames.44 FLG is also essential in maintaining the skin barrier 
and preventing trans-epidermal water-loss. The gene encoding FLG is located on 
chromosome 1q21, as is a cluster of genes known as the Epidermal Differentiation Complex 
(EDC). Two common loss-of-function mutations in the gene encoding filaggrin, R501X and 
2282del4, have been shown to be the cause of ichthyosis vulgaris. In addition, these mutations 
are major risk factors for the development of atopic dermatitis as well as asthma associated 
with atopic dermatitis and systemic allergies. The mutations are relatively common, and occur 
in approximately 9% of individuals of European origin.12 Among European patients with 
atopic dermatitis, this mutation is identified in about 30%.9 
When studying the family history of atopic dermatitis in an epidemiological perspective, a 
maternal line of inheritance is most often reported.45-47  Later studies on family history have 
indicated that a paternal line of inheritance is equally related to disease development as the 
maternal line.48, 49  
 
Etiology - Environmental factors 
The increase in allergy related diseases over the past decades indicates the importance of an 
environmental influence. The “hygiene hypothesis” was first introduced in 1989 by a British 
study, hypothesizing that declining family size, improvements in household amenities and 
higher standards of personal cleanliness had reduced cross infections in young families, and 
thereby led to an increase in allergic diseases such as hayfever and eczema.50 Findings from a 
German study, with increase in incidence of atopy and hayfever among children in former 
East-Germany, led investigators to believe that the changes were related to our Western 
19 
 
lifestyle.51  Normally, microbial exposure in early life will make the immune system switch 
from a Th2 dominant response (present at birth) to a Th1 dominant response. Lack of this 
microbial environmental exposure in early life may lead the immune system to remain in a 
Th2 dominant, allergy-primed state. The protective effect of hygiene-related factors (such as 
birth order/family size, day care attendance and exposure to farm life) observed in several 
studies has mainly been related to allergy, hayfever and asthma.52-60 The same risk factors that 
consistently are associated with asthma do not hold true for eczema.52, 61 As the hygiene 
hypothesis has little to do with hygiene the way we usually define it, suggestions have been 
made to change the term to “the microbial deprivation hypothesis”.62 Several authors have 
studied the gut and differences in the composition of the intestinal microflora between allergic 
and non-allergic young children.63-65 The first attempt to introduce the hygiene hypothesis 
into clinical practice was done by oral administration of probiotics. The aim was to prevent 
allergies in children.66 Since then, several studies on probiotics and possible prevention of 
allergies/allergy related diseases have been conducted. Although results have been 
conflicting, there is some evidence to suggest that probiotics given as a supplement ante- and 
postnatal can reduce eczema risk in infants from high-risk families.67 In a sub-study from 
PACT women received probiotics from week ≤ 36 of pregnancy and the three first postnatal 
months during breastfeeding. The cumulative incidence of eczema at age 2 years was 
significantly reduced in the offspring of those without a family history of eczema.68        
Other environmental risk factors for eczema not directly related to the hygiene hypothesis 
have also been investigated, and there is some evidence of a higher risk of eczema for those 
living in urban compared to those living in rural areas.69 There have also been studies 
showing that environmental factors, such as exposure to cat within the first year of life of 
those carrying FLG mutations, can alter the expression of different genes.70 Environmental  
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factors easily manipulated at a population based level in order to prevent further increase in 
eczema prevalence have so far not been identified.25   
 
Pathogenesis  
During the last decade there has been a paradigmatic shift in our understanding of the 
mechanisms causing eczema, with a switch from a purely immunological concept to a 
combination of structural abnormalities and immunological dysregulation.71 There is a close 
and complex relationship between the skin barrier and the immune abnormalities, and this 
relationship is not yet fully elucidated. The skin inflammation in ezema is characterized by an 
infiltration in the skin of activated CD4+ T-lymphocytes, mast cells, dendritic cells, 
macrophages and eosinophilic granulocytes.72 When proteins penetrate the skin, they will be 
recognized by the dendritic cells. The dendritic cells migrate to the regional lymph node 
where they activate naïve T-cells into differentiated Th2-cells. These Th2 cells produce IL-4 
and IL-13 which in turn activate B-cells into IgE-producing plasma-cells. IgE binds to the 
mast-cell receptor FcεR and under normal circumstances this will lead to the development of 
tolerance. In patients with allergies, however, re-activation of the FcεRs by antigens will 
trigger a cascade of intra-cellular signals leading to mast-cell deactivation. This can cause an 
allergic reaction either locally or systemically.73 The cytokine thymic stromal lymphopoietin 
(TSLP) also have a central role in the development of allergic responses. TSLP is a potent 
activator of the dendritic cells leading to a Th2 polarized cytokine-profile dominated by IL-4, 
IL-5 and IL-13 as well as production of several potent chemokines. In addition, TSLP is an 
important activator of mast cells and is up-regulated in keratinocytes of atopic dermatitis skin 
lesions.74 Another important subgroup of T-cells in atopic dermatitis is the Th-17 cells. Th-17 
cells activate neutrophilic granulocytes and produce IL-17 and IL-22. These two interleukins 
are activators of the keratinocytes.  
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There are also other factors important for the maintenance of AD. Human skin’s innate 
immune system produces antimicrobial peptides such as cathelicidin, human β-defensins and 
dermcidin. These peptides accumulate in skin affected by inflammatory diseases. In a study 
comparing psoriasis and AD, cathelicidin and human β-defensin2 was significantly decreased 
in the skin from patients with AD.75 The up-regulation of IL-4 and IL-13 in atopic skin could 
account for the low expression of human β-defensin2. This down-regulation of antimicrobial 
peptides in atopic skin makes it more difficult to manage microbial infections such as 
Staphylococcus aureus, fungi and viruses.76 Most patients with AD have their skin colonized 
with S.aureus. Suppression of the innate immune system, scratching with increased binding of 
S.aureus and release of S.aureus enterotoxins all contribute to severity of the disease, 
sensitization and increased inflammation.9, 77  
IL-31 is a T-cell derived cytokine associated with itch, and is over-expressed in AD lesional 
skin.78 In a murine model antibodies against IL-31 reduced scratching behavior, but did not 
affect the amount of skin lesions.79  
When the foetus is in utero, it has a Th2 dominant lymphocyte and cytokine profile. This is of 
crucial importance in order for the maternal immune system to accept the foetus.80, 81  
Postnatal, probably as a consequence of stimulation by different infectious agents, the Th2 
profile characteristic of the adaptive immune system changes into a Th1 profile characteristic 
of the innate immune system.82 This skewing of the immune system towards a Th1 profile 
does not occur during the first month of life in atopic individuals, and atopic individuals will 
maintain immunological reactions of Th2 type as well as a Th2 cytokine profile.83  Factors 
related to the Western life-style leading to reduced bacterial diversity, such as vaccination, 
increased use of antibiotics and fewer siblings, among others, are also thought to support the 
development of this Th2 dominance.50, 51, 84, 85  This immunological “imbalance” can, 
however, only partly explain the complex immunology leading to allergic diseases such as 
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eczema. More recent studies have hypothesized that regulatory T cells and their cytokines 
play an important role in the protection against allergies. Microbial stimulation of dendritic 
cells via Toll-like receptors in the gastrointestinal mucosa or other lymphoid tissues may 
induce this protection.86  
 
Diagnostic criteria 
When studying atopic dermatitis different diagnostic criteria have been used. Brenninkmeijer 
el al have identified ten different criteria and evaluated the evidence concerning the validity of 
these different criteria (Table 1).87  
 
 
 
 
 
Hanifin and Rajka diagnostic criteria from 1980 are the most well-known. In order to be 
identified as a case the person under study is required to have three out of four major criteria, 
or four out of five in a more recent version, in addition to three out of 33 minor-/sub-criteria. 
88, 89 Despite varying specificity the validity in two hospital-based studies showed good 
Table 1. Different diagnostic criteria for atopic dermatitis (Copyright 2008 Wiley. 
Used with permission from Brenninkmeijer EEA et al,Diagnostic criteria for atopic 
dermatitis: a systematic review. Br J Dermatol. 2008 Apr;158(4):754-65. John Wiley 
and Sons) 
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outcomes.90, 91 However, due to the long list of minor criteria, out of which some are 
nonspecific, the criteria are not suitable for epidemiological studies.  
The United Kingdom working party (UKWP) diagnostic criteria were developed as a 
refinement of the Hanifin and Rajka criteria and are recommended used as a 12 month period 
prevalence measure.92 This set of criteria is the one mostly validated both in hospital and 
community settings. In a community survey in London the UK criteria had a sensitivity of 
80% and a specificity of 97%.87, 90, 93   
. 
Severity outcome measures 
A systematic review performed by Schmitt et al identified 20 named scales of eczema 
outcome measure.94 Only three of them, SCORAD (Severity Scoring of Atopic Dermatitis 
index), POEM (Patient-Oriented Eczema Measure) and EASI (Eczema Area and Severity 
Index) had been tested sufficiently and performed adequately. NESS (Nottingham Eczema 
Severity Score) was found to have an adequate inter-observer reliability. 
The SCORAD system was developed as a consensus by the European Task Force on Atopic 
Dermatitis in 1993.95 EASI is validated in several studies, all of whom are carried out in 
secondary/tertiary care, whilst POEM also is validated in primary care.94    
NESS is a refinement of the Rajka and Langeland grading system proposed in 1989.96, 97 This 
scoring system meets the requirements of a population research tool, such as simplicity and 
good validity. It also incorporates the chronicity, extent and intensity of the disease. The 
scoring system is, however, only validated for children 1-5 years of age.  
Because outcome measures are so different in different trials, therapies evaluated in different 
studies are not always comparable. As a response to this, an international Delphi exercise on 
outcome measures for atopic dermatitis – Harmonizing Outcome Measures for Eczema 
(HOME) has been held.98 Consensus was achieved for inclusion of symptoms, physician-
assessed clinical signs and a measurement for long-term control of flares in the core set of 
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outcome domains for eczema trials. The tools used to assess these outcomes are, however, yet 
to be agreed upon.  
 
Allergic diseases related to eczema 
Eczema is closely related to other allergy related diseases such as food allergy, asthma and 
rhino-conjunctivitis. In children symptoms of eczema often precedes symptoms from the 
airways, and early manifestation of eczema is observed to be associated with an increased risk 
of asthma and rhino-conjunctivitis.99-101 The atopic constitution starting with food allergy and 
proceeding to eczema, asthma and rhino-conjunctivitis is often referred to as the atopic march.  
Food allergies will not be covered in this thesis.   
 
Asthma 
Asthma is defined as a chronic inflammatory disorder of the airways and is associated with 
airway hyper-responsiveness that leads to recurrent episodes of wheezing, breathlessness, 
chest-tightness, and coughing.102 In children, asthma is described as “repeated attacks of 
airway obstruction and intermittent symptoms of increased airway responsiveness to trigger 
factors such as exercise, allergen exposure and viral infections”.103 It is a heterogenic disease, 
and in children 5 years and younger the symptoms are variable and non-specific.104 Since 
main pathologic hallmarks cannot be assessed routinely in this age-group, a descriptive 
approach of recurrent episodes of chough and/or different types of wheeze has been 
recommended. Because there are differences in asthma presentation among children in 
different age-groups, both diagnostic and treatment strategies are based on age.105 In infants 
(0-2 years), persistence of symptoms is a major indicator of severity. If the infant has 
wheezed on most days of the week during the last 3 months, a diagnosis of persistent infantile 
wheeze should be made. In pre-school children (3-5 years) asthma diagnosis is made if the 
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child has persistent symptoms during the last year. Symptoms can be virus-induced, exercise-
induced or allergen-induced. School-children (6-12 years) also have persistence of symptoms 
during the last year as the key differentiator. In this age-group, however, allergen-induced 
symptoms are more common. Diagnosis of asthma in young children is only possible through 
long-term follow-up.   
Early allergic sensitization is a major risk factor for persistent asthma.104, 106, 107 In a large 
cross-sectional study performed in 8-12 year old children according to standardized 
methodology of Phase Two of the ISAAC the link between atopic sensitization and asthma 
symptoms differed strongly between different populations and increased with economic 
development.108 Current wheeze attributable to atopic sensitization ranged from 0% in Ankara 
(Turkey) to 93.8% in Guangzhou (China). In a Norwegian study, where dispensed anti-
asthmatics were used as a proxy for current asthma, the prevalence of asthma among 7-years 
old children was 6.5%.109   
Management of asthma for children up to 5 years of age are given by the Global Initiative of 
Asthma (GINA)102, whereas the PRACTALL consensus report also give recommendations for 
treatment of older children.105  
 
Allergic rhinitis 
Allergic rhinitis is characterized by episodes of sneezing, itching, rhinorrhea and nasal 
obstruction resulting from an immunologically mediated hypersensitivity reaction in the 
nose.15 Conjunctivitis often accompanies the rhinitis and whenever necessary the two terms 
combine, as in allergic rhino-conjunctivitis. Allergic rhino-conjunctivitis is mostly IgE 
mediated. Classification of allergic rhinitis according to duration and severity is suggested by 
the World Health Organization initiative, “Allergic Rhinitis and Its Impact on Asthma”, 
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(ARIA).110 Allergic rhinitis is subdivided into intermittent allergic rhinitis (less than 4 days a 
week or less than 4 consecutive weeks) and persistent allergic rhinitis (more than 4 days a 
week for more than 4 consecutive weeks), and classified as “mild” or “moderate/severe” 
depending on severity of symptoms and impact on social work, school and work. The 
prevalence of reported rhinitis-symptoms in 6-7 years old children from ISAAC phase III 
varies from 2.2% in Iran to 24.2% in Taiwan.111 In a Norwegian study among 9-11 years old 
children the prevalence of self-reported symptoms of allergic rhinitis had increased from 
16.5% in 1985 to 29.6% in 2000.112 In a French study, reported prevalence of symptoms of 
allergic rhinitis among 18 months old children were 9.1 %.113 Diagnosis of allergic rhinitis in 
preschool children is difficult, as symptoms resemble those of infectious rhinitis. The clinical 
definition of allergic rhinitis implies knowledge of immune response. Since clinical 
examination of large populations represents a major challenge, standardized definitions of 
allergic rhinitis suitable for use in an epidemiological setting are lacking.110 This makes 
comparison of prevalence of allergic rhinitis in different studies difficult.   
 
The atopic march 
The natural history of atopic manifestations and the subsequent age-dependent progression of 
different atopic manifestations are often referred to as the atopic march.114, 115 The majority of 
children with eczema appear to “grow out” of their disease, and about 60% of childhood 
patients are free of disease symptoms in early adolescence.116 However, a family history of 
atopy, early onset of eczema, severe eczema and early sensitization are commonly held to be 
the main risk factors for developing asthma or allergic rhino-conjunctivitis. Some authors 
have argued that rather than a progressive development from atopic dermatitis to asthma, a 
distinct phenotype of atopic dermatitis co-existing with wheeze predisposes for asthma.117 
Others have found that in non-sensitized children eczema rather than wheeze or rhinitis 
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predicts subsequent sensitization.118 The skin barrier dysfunction with the chronic skin 
inflammation can facilitate penetration and sensitization to allergens and thus the transition 
from non-atopic to atopic eczema. In this way the skin can be the entry point for further 
allergy related disorders, and the start of the atopic march.9, 119 Support to the role of the 
barrier dysfunction and its importance in the pathogenesis of sensitization is given by the 
findings of an increased risk of IgE mediated peanut allergy among people with FLG 
mutations.120 Several investigators have argued that a possible prevention of the atopic march 
can be achieved by therapies that modify eczema severity and restore the skin barrier.115, 121, 
122   
 
Impact of eczema 
Eczema adversely affects the quality of life primarily in patients suffering from the disease, 
but secondarily also in people living in close relation to them, such as family, parents and 
siblings.123-125  Children with eczema may have itch and disturbed sleep leading to impaired 
school performance and emotional stress.126  In addition to the immediate impact, eczema 
may also influence carrier choice, affect close relationships, social development and 
maturing.127  Several investigators have found an association between atopic dermatitis and 
reduced mental health.128-130 To estimate psychological distress in populations, different 
instruments have been used. One of them is the Hopkins Symptom Checklist (SCL). A five-
item version is validated in Norwegian, and measures mental distress along two dimensions, 
namely depression and anxiety.131  The SCL-5 is suitable as a screening-instrument, and used 
in several health surveys conducted in Norway.132       
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AIMS 
 
The aims of the thesis were to investigate: 
 
1. The prevalence and severity of eczema among 2-years old children in Trondheim 
 
2. Whether eczema in 2-years old children follow a maternal or a paternal line of 
inheritance  
 
3. If eczema in 2-years old children is associated with asthma at age 6 years?  
 
4. The association between eczema and mental distress in adolescents 
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MATERIAL AND METHODS 
The Prevention of Allergy among Children in Trondheim (PACT) study 
The Prevention of Allergy among Children in Trondheim (PACT) study was established in 
2000 and conducted in primary health care as a controlled intervention study. The 
intervention aimed at reducing tobacco exposure, reduce indoor dampness and increase the 
intake of omega-3-fatty acids and oily fish, and thereby to reduce the incidence of allergic 
diseases among children in Trondheim. The study is a collaboration between the Municipality 
of Trondheim and NTNU.133  
Trondheim is the largest city in central Norway, has about 170 000 inhabitants and 
approximately 2100 deliveries per year. In all, 32 of 35 general practices (104 GPs), all seven 
community-based midwives and all 20 maternity health centres in Trondheim agreed to 
participate. Three single practices refused to participate, and in addition four group practices 
withdrew from including women to the intervention cohort.   
The intervention cohort included only pregnant women. The women were consecutively 
recruited when attending ordinary scheduled appointment with GPs or midwives. Inclusion to 
the intervention cohort started in July 2002 and ended in June 2006. A 6-year follow-up of the 
intervention cohort is still on-going, and will end December 2012 (Figure 3).  
To monitor changes in lifestyle and diet habits and trends in incidence of allergy related 
diseases over time, a control cohort was established one years prior to the intervention cohort. 
The design of the control cohort is that of cross-sectional inclusion of yearly cohorts of 
pregnant women and children 6 weeks, 1 year, 2 years and 6 years of age. Inclusion to the 
control cohort started in September 2000 and ended March 2009. Inclusion to the control 
cohort ended when the intervention started for that actual age-group (e.g. when the first 
children in the intervention cohort reached 6 weeks of age, inclusion of 6 week olds to the 
control cohort stopped etc).  In addition to the cross-sectional design of the control cohort,  
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children with more than one completed questionnaire could be followed prospectively.   
All women who had children in one of these cohorts, who received an invitation and were 
willing and able to complete a questionnaire in Norwegian, were included in the study.  
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* Total population of birth cohort in Trondheim during inclusion period 
† Questionnaire on behavior and risk factors 
‡ Questionnaire on health  
 
 
Control cohort  
(Cross-sectional) 
 
Children 6 weeks postnatal: 
N*=4900 
 
Inclusion: 
Started September 1st 2000 
Stopped December 31th 2002 
Control cohort  
(Cross-sectional) 
 
Pregnant women at first 
antenatal check-up: 
N*=3675 
 
Inclusion: 
Started September 1st 2000 
Stopped May 31th 2002 
Control cohort  
(Cross-sectional)  
 
Children 2 years postnatal: 
N*=9100 
 
Inclusion: 
Started September 1st 2000 
Stopped March 31th 2005 
Questionnaire Q3 † 
1 year of age 
 
n=3892 
Control cohort  
(Cross-sectional) 
 
Children 1 year postnatal: 
N*=7000 
 
Inclusion: 
Started September 1st 2000 
Stopped December 31th 2003 
Questionnaire Q4 † 
2 years of age 
 
n=4823 
 
Questionnaire Q5 ‡ 
2 years of age 
 
n=4795 
Intervention cohort 
(Longitudinal follow-up) 
 
Pregnant women at first 
antenatal check-up:  
N*=8400 
 
Inclusion  
Started June 1st 2002 
Ended May 31th 2006 
Questionnaire Q2 † 
6 weeks of age 
 
n=1685 
Questionnaire Q3 † 
1 year of age 
 
n=1214 
Questionnaire Q4 † 
2 years of age 
 
n=1267  
 
Questionnaire Q5 ‡ 
2 years of age 
 
n=1266 
Questionnaire Q2 † 
6 weeks of age 
  
n=3142 
Questionnaire Q1 † 
First antenatal 
check-up 
 
n=1790 
Questionnaire Q1 † 
First antenatal 
check-up 
 
n=2860 
n=1685 
n=1004 
n=861 § 
n=210 
n=107  
n=292 
Control cohort  
(Cross-sectional) 
 
Children 6 years postnatal: 
N*=17500 
 
Inclusion: 
Started September 1th 2000 
Stopped December 31th 2008  
Questionnaire Q6 ‡  
6 years of age 
 
n=7700 
Figure 3. Flow-chart of the PACT study. 
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The Young-HUNT 1 survey 
The Young-HUNT Study is the youth part of The Nord-Trøndelag Health Study (HUNT). 
The HUNT study is a comprehensive population-based study and has been conducted three 
times since 1984, comprising data from questionnaires, interviews, clinical investigations and 
blood/urine samples. The first HUNT survey (HUNT 1) was conducted in 1984-86 and 
included only adults 20 years and older. In 1995-97 the HUNT 2 also included adolescents 
aged 13-19 years (Young-HUNT 1). In 2000-2001 a follow-up survey of students attending 
the last two years of high school were conducted (Young-HUNT 2). Young-HUNT 3 was part 
of the third wave of the HUNT 3 survey, conducted from 2006-08 and included all inhabitants 
of the county 13 years and older.  
 The primary aim of the Young-HUNT 1 study was to survey health, diseases and lifestyle 
among adolescents. 
Nord-Trøndelag County is one of 19 Norwegian counties, located in central Norway, south of 
the Arctic Circle (Figure 4). The total population in 1995 was 127 000, and in 2009 130 000. 
The county is mostly rural but has 6 cities, the largest is Steinkjer with 20 800 inhabitants 
(2009).134  
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Subjects included in the thesis 
The PACT study 
Paper I, II and III 
In the yearly cross sectional control cohort, the participation rate varied from 49% to 64% for 
the different age groups. For the intervention cohort, 8400 pregnant women were eligible 
during the inclusion period. Only 2860 women were included, giving a participation rate of 
34% (Figure 3).  
In paper I we used information from the control cohort on child’s health at 2 years obtained 
by January 2005 (n=4784).  
In paper II we used information from 2657 children whose parents had completed both the 
questionnaire on exposure 6 weeks and child’s health 2 years. In addition, we used data from 
Figure 4. Norway, Nord-Trøndelag and Trondheim 
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3087 children with information on exposure at 1 year and health at 2 years. As we only 
studied association, the participants were from both the intervention cohort and the control 
cohort. 
In paper III we used the control cohort to prospectively follow 4780 children who had 
completed both the questionnaire on exposure and on health at age 2 years. Some 2192 (46%) 
answered the questionnaire on health at age 6 years. These children comprised the study 
population in paper III. 
 
The Young-HUNT 1 survey 
Paper IV 
A total of 9917 students in junior high schools (13-16 years) and high schools (17-19 years) 
were invited. The participation rate was 91%. 12-year olds (n=127) and 20-year olds (n=40) 
were excluded, leaving 8817 students (89%) eligible for further analyses. Non-participants 
were mostly not in school the day of the study, did not want to participate or did not get 
consent from their parents (less than 1%).135 
 
The Clinical Investigated Subsample 
Paper I and III 
From March 2001 to September 2002 a random sample of 720 pregnant women from the 
control cohort of PACT were invited to a sub-study, the IMPACT study. The primary aim of 
the IMPACT study was to investigate the intestinal microbiota composition and its impact on 
the immune system.136 When their offspring reached 2 years of age, 441(61%) were eligible 
for follow-up. These 441 children were invited to a follow-up examination by a paediatrician 
or a dermatologist. The examinations were carried out from May 2003 to January 2005 and 
included clinical examination, skin prick test (SPT) and venous sampling. Some 390 children 
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(54%) met. SPT was successfully completed in 304/390 (80%), whereas venous sampling was 
carried out among 258/390 (66%). Allergy test (either STP or measurement of sIgE) was 
completed in 355/390 (91%).     
 
Questionnaires/Data collection 
The PACT study 
Questionnaires on different lifestyle factors were distributed by GPs, midwives and health-
workers to pregnant women and parents of children aged 6 weeks, 1 year and 2 years. At 
child’s age 2 years and 6 years, a detailed questionnaire on child’s health was completed 
(Appendix 1). The lifestyle questionnaire included questions on family eczema history, 
infections, diet habits, tobacco exposure and indoor climate. Questionnaire on health 
emphasized symptoms related to allergic diseases, and several of the questions were obtained 
from the International Study of Asthma and Allergy in Childhood (ISAAC). However, since 
validated questionnaires were not available for 2 year olds, the ISAAC questions were 
adapted from various sources to fit this actual age group.137-140 The questionnaires were 
identifiable by a participant number. After completion the questionnaires were put in 
envelopes with prepaid postage and returned to the study office. 
 
The Young-HUNT 1 survey 
The questionnaire included questions on mental and somatic health, life-style, quality of life 
and detailed information on symptoms of allergy related diseases (Appendix 2). The latter 
were based on the ISAAC questionnaire.141 Prior to the Young-HUNT 1 survey, a pilot study 
testing the questionnaire was carried out and included one sample of eight graders in junior 
high school (14-15 years) and one sample of student attending the second year of high school 
(17-18 years).  
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All students attending the Young-HUNT 1 completed the self-administered questionnaire 
during one school hour. The questionnaires were only identifiable by a bar code of the 11-
digit personal number given to all Norwegians either at birth or when granted citizenship. All 
students put their completed questionnaire in a clean envelope and sealed it. The envelopes 
were collected by a project field worker.   
 
The Clinical Investigated Subsample 
Parents of children attending the subsample had completed the PACT questionnaires on 
lifestyle and health at child’s age 2 years. In addition, they underwent a structured interview 
which emphasized symptoms related to allergy related diseases. Moreover, the children had a 
thorough inspection of the skin, and eczema diagnosis was defined according to the UKWP 
diagnostic criteria. The examination was carried out by two experienced physicians (IS 
paediatricians and MS dermatologist). To ensure agreement upon both diagnosis and severity 
scoring, the first 30 children were examined by both physicians. Clinical examination of the 
remaining children was evenly apportioned by the physicians. If the child had eczema upon 
examination, severity was assessed with both SCORAD and NESS.  
-UKWP diagnostic criteria 
In order to qualify as a case of atopic eczema with the UK diagnostic criteria, the child must 
have had an itchy skin condition in the last 12 months plus three or more of the following: i) 
onset below age 2 (not used in children under 4 years), ii) history of flexural involvement, iii) 
history of a generally dry skin, iv) personal history of other atopic disease (or history of atopic 
disease in first-degree relative in those under 4 years of age), v)visible flexurale dermatitis as 
per photographic protocol.142 Flexural dermatitis is dermatitis located around the eyes, around 
the sides or front of the neck (any patch of dermatitis larger than 1 cm in diameter in an area 
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defined by the jaw bone above and clavicles below, and a line drawn vertically downwards 
from the ears with the head in an upright position looking directly forward), front of elbows 
(any patch of dermatitis larger than 1 cm in diameter affecting one or both elbow creases 
within an area marked out by the subject's palm), behind knees ( any patch of dermatitis larger 
than 1 cm in diameter affecting one or both areas behind the knee within an area marked out 
by the subject's palm) and front of ankles (any patch of dermatitis larger than 1 cm in 
diameter affecting one or both fronts of ankles within an area marked out by the subject's 
palm). In addition for children under the age of 4 are cheeks (any patch of dermatitis greater 
than 2 cm in diameter involving one or both cheeks), forearms (at least one patch of 
dermatitis greater than 2 cm in diameter on each forearm (i.e. elbow to wrist)) and legs (at 
least one patch of dermatitis greater than 2 cm in diameter on each leg (i.e. knee to ankle)). 
-SCORAD 
The SCORAD index consists of the interpretation of A: the extent of the disease (according to 
the rule of nines; 20% of the score) B: the intensity composed of six items (erythema, 
oedema/papules, effect of scratching, oozing/crust formation, lichenification and dryness, 
60% of the score. Each item has four grades, 0-3) and C: subjective symptoms (itch and 
sleeplessness, 20% of the score).143 The score is achieved by the formula A/5+7B/2+C, and 
the maximum score is 103. The evaluation is performed within 7-10 minutes. Eczema is 
graded as mild when the score is <25, moderate when 25-50 and severe when >50. Based on 
training sessions, the task force later on modified the SCORAD, recommending only the 
objective SCORAD being used.144 The objective SCORAD only considers the extent and 
intensity of the eczema. The formula is then A/5+7B/2, giving a maximum score of 83. 
Eczema grading is then mild when the score is <15, moderate when 25-40 and severe when 
>40.  
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-NESS 
The following parameters are evaluated when assessing the NESS; A: clinical duration, B: 
intensity (measured as sleep disturbance) and C: extent of disease involvement. Each of these 
parameters have been given equal weighting, and graded on a five-point scale from 1 to 5.  
The surface area measurement is assessed by using tick boxes. Investigators record a tick in 
each box if more than 2 cm2 is involved with AD. The total number of ticks is calculated by 
adding together the number of ticks for both the front and the back of the surface diagram.  
Each parameter’s score (A, B and C) is added to produce the total score. Minimum score is 3 
and maximum score is 15. Severity is then graded according to the final score as follows: 3-8 
mild degree, 9-11 moderate degree, 12-15 severe degree.96  
 
-Skin Prick Test (SPT) 
Trained project workers performed skin prick testing according to the ISAAC procedure.145 
The following standardized extracts from Soluprick® allergens (ALK Albello, Denmark) 
were used: mite (Dermatophagoides pteronyssinus), mould (Cladosporium herbarum), cat and 
dog dander, birch, timothy (grass) and mugwort pollens, hen’s egg white, codfish, hazelnut 
and peanut. For cow’s milk fresh skimmed milk was used. In addition, two positive histamine 
control (Histamine 10mg/ml) and one diluents-negative control (NaCl) were applied on the 
volar surface of child’s forearms. Before testing, the parents were told to cease child’s 
antihistamine use and avoid the use of steroid creams on the forearms one week prior to 
testing.146 The test was read after 15 minutes, and a mean diameter of at least 3 mm greater 
than the negative control was considered positive test.147 
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-Specific IgE 
Sera from venous blood samples were analyzed for sIgE using assays testing for the same 
allergens as the SPTs. The children were offered epicutaneous anaesthesia with EMLA™ 
cream (AstraZeneca, Ltd, London, U.K.) prior to venous sampling attempt, which was carried 
out only once. The sIgE analyses were performed in the immunology laboratory at St. Olavs 
University Hospital, Trondheim, using Immulite® 2000 Allergen-specific IgE system 
(Siemens Medical Solutions Diagnostics, Deerfield, IL, U.S.A.). A sIgE ≥0.35 kUL-1 was 
considered positive.  
 
Study variables 
All variable definitions used in Paper I-IV are described in each paper, and all variables are 
listed in the appendices.    
 
Variables in the PACT study 
Exposure variables were collected in the questionnaires on life-style and risk factors 
completed by the mother/parents during pregnancy, when the child was 6 weeks, 1 year and 2 
years of age. The questionnaires covered the following topics; number of siblings, parietal 
status, birth-weight/length, vaccination, marital status, symptoms of allergy related diseases in 
mother, father and sibling(s), pregnancy conditions, housing conditions, indoor dampness, 
semi-quantitative food frequency data for mother and child, smoking habits in parents and 
information on child care. Explanatory variables used in paper II were eczema in any family 
member, breastfeeding, keeping a dog, homeowner, age of mother at time of childbirth, 
smoking habits in mother and sex. In paper III the following explanatory variables were used; 
eczema at 2 years (from the 2-year health questionnaire), wheeze, atopy in family, smoking 
habits in mother, homeowner, sex and sensitization (from Clinical Investigated subsample).  
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Outcome variables were assessed from the questionnaires on health completed at age 2 years 
and 6 years. In developing these questionnaires, three requirements had to be met. First, the 
extent of the questionnaires should suffice estimation of the common allergy related diseases, 
and the use of health care services and treatment of these diseases. Second, completing the 
questionnaires should not take more than 30 minutes. And third, they should be designed to 
obtain satisfactory validity. The reliability of ten of the questions in the health questionnaire 
was tested, and compared to information collected from medical records.148 
Parent-reported eczema at age 2 years (paper II) and asthma 6 years (paper III) were used as 
outcome variables. 
 
Variables in the Young-HUNT 1 
All exposure and outcome variables used in the Young-HUNT study (paper IV) were assessed 
from the questionnaire. The definition of “atopic dermatitis” in paper IV differs slightly from 
how we defined “atopic dermatitis” and “eczema” in the PACT study, but as in the other 
papers, the term is used without any knowledge of sensitization and should therefore be 
regarded as “eczema” according to the WAO recommendations.      
The SCL-5 score was identified by 5 different questions on a four-point scale ranging from 
1=”not at all” to 4=”extremely”. The score covers two dimensions, namely depression and 
anxiety, and are related to the two last weeks. A total SCL-5 score of 2 or more was 
considered positive for mental distress. 
The questions on headache and neck/shoulder pain had four response categories; “never”, 
“seldom”, “sometimes” and “often”. These variables were dichotomized into 
“never/seldom/sometimes” and “often”. 
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Variables in the Clinical Investigated Subsample  
In the subsample, AD was diagnosed according to the UKWP diagnostic criteria. In addition, 
the clinicians used an 8-point visual analog scale (VAS) to make an on-site evaluation of the 
likelihood that the child had AD. The evaluation was based on the clinical experience of the 
physicians, and a score of 8 indicated that the physician was sure about the diagnosis. 
Severity of AD was assessed by SCORAD and NESS. We only used the adjusted objective 
measures of SCORAD (score 0-83) and defined disease severity as mild when the score was 
<15, moderate when the score was 15-40 and severe when the score was >40. The NESS 
score ranges from 3-15, and AD was graded as mild moderate or severe if the score was 3-8, 
9-11 and 12-15, respectively. 
Sensitization was tested by SPT and/or sIgE, and the child was considered sensitized if either 
SPT or sIgE was positive. 
 
Statistical analyses 
In paper I, II and IV data were analyzed using SPSS for Windows version 10.0, version 13.0 
and version 15.0, respectively (SPSS Inc., Chicago, IL, USA). In paper I and II, prevalence 
with 95% confidence intervals (CI) were estimated using STATA for Windows version 10.0 
and version 11.2 (College Station, Texas, USA). In paper III, all analyses were performed 
using STATA for Windows version 11.2 (College Station, Texas, USA).  
Paper I. Symptoms related to eczema in boys and girls were compared using the Pearson chi-
squared test. All reported p-values were two-sided. Prevalence was reported with 95% 
confidence intervals (CI) based on binomial distribution.  
Paper II. Family eczema history was categorized into 7 different categories, with no family 
eczema history as the reference category. Univariate associations for different categories and 
eczema at 2 years of age were studied using simple logistic regression. Adjusted associations 
44 
 
were estimated using logistic regression. Adjustments were made for confounders defined by 
a priori knowledge. Associations were reported as odds ratios (OR) with 95% CI for 
binominal distributed data. 
Paper III. Baseline characteristics as well as allergy related diseases were described as 
prevalence with 95% CI for dichotomous variables, and mean with +/-standard deviation (SD) 
for continuous variables. Multivariable, logistic regression models were used to obtain 
adjusted associations between ever eczema at 2 years and current asthma at 6 years. Two 
different models were made. In one model, the explanatory variable was eczema, whereas in 
the other model, age of onset of eczema was used as the explanatory variable. Age of eczema 
onset was divided in tertiles (0-3months, 4-12 months, 13 months or older), and all other 
explanatory variables in model were dichotomized. The possible confounding factors were 
identified by a priori knowledge. Due to the large number of missing data, we used multiple 
imputations (MI) to assess potential impact of missing data in the regression analyses. We 
assumed that data were missing at random given the observed data and used chained 
equations (regression switching) with 50 sets of imputations to impute missing values as 
implemented in the STATA’s ICE command. The following predictor variables reported at 2 
years were included in the imputation model: eczema, age of onset eczema in tertiles, 
siblings, atopy in family, cat in household, symptoms of wheeze/whistling in chest, symptoms 
of hayfever, ever hospitalized due to any allergy related disease, homeowner, smoking 
mother/father and sensitization. In addition the outcome variable current asthma 6 years was 
included. Since reported sensitization was considered not missing at random, sensitization-
data from the sub-population, where all the randomly selected participants included were 
tested regardless of disease symptoms or not, were used as predictor in the ICE command. A 
multiplicative interaction term between eczema and sensitization was also included in the 
predictive ICE command and tested in the final models.  
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For each outcome variable, a separate MI dataset was created, and resulting estimates were 
combined by the MIM command in STATA. To study the association between early eczema 
and current asthma at 6 years, logistic regression analyses were performed on the MI dataset.   
All results are presented as adjusted odds ratios (aOR) with 95% CI estimated for binominal 
distributed data. In addition to the multiple imputation approach, we also performed analyses 
based on individuals with complete data. 
Paper IV. Prevalence of different symptoms of mental distress, mental distress and atopic 
dermatitis among boys and girls were reported with 95% CI. Unadjusted odds ratios between 
different chronic diseases and mental distress were estimated and reported as ORs with 95% 
CI. Variables included in the model were dichotomized. Multiplicative interaction was tested 
between sex and atopic dermatitis. Since the interaction term was significant, we did sex-
stratified analyses. Adjusted ORs with 95% CI were estimated by using logistic regression 
models. 
 
ETHICS 
Parents of participating children in the PACT study signed a written consent to participate in 
the PACT study, and specific consent was given to allow skin prick test and venous sampling 
for children included in the clinical investigation subsample.  
In the Young-HUNT study all participants and parents of children under 16 years of age 
signed a written consent to take part in the study.  
The Regional Committee for Medical Research Ethics approved both PACT and Young-
HUNT. The Norwegian Data Inspectorate Board approved establishment of the research 
registers.  
The PACT study is registered in The Current Controlled Trials registration, 
ISRCTN28090297. 
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MAIN RESULTS 
Review of paper I 
Atopic dermatitis among 2-year olds; high prevalence, but predominantly mild disease – 
The PACT Study, Norway 
Objective: To study the prevalence and severity of eczema among 2-years old children. 
Methods: Questionnaires on health from a total population of 4783 2-years old children and 
clinical data from a random subsample of 390 children were used. All children were included 
in the control cohort of the PACT study. Eczema diagnosis was made according to reported 
symptoms in questionnaires. In addition, the UKWP criteria were used to assess eczema 
diagnosis in the random subsample. Both Severity Scoring of Atopic Dermatitis (SCORAD) 
and Nottingham Eczema Severity Score (NESS) measured severity outcome in the subsample. 
Results: The prevalence of ever eczema in the total population was 16.5% (95% CI 15.5-17.6) 
when information was obtained from questionnaires. In the random subsample the 
corresponding prevalence was 20.6% (95% CI 16.6-24.6). When eczema in the random 
subsample was diagnosed according to the UKWP criteria, the prevalence was 15.9% (95% 
CI 12.3-19.5). More than 70% of the children diagnosed with eczema according to the UKWP 
criteria had mild disease.   
Conclusion: We found a high prevalence of ever eczema at 2 years of age. However, more 
than two thirds of the cases were mild, which may imply that eczema as a risk factor for 
future allergy related disorders is limited.   
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Review of paper II 
Family eczema-history in 2-year-olds with eczema; a prospective, population-based 
study. The PACT-study, Norway. 
Objective: To prospectively study the association of reported eczema in mother, father and 
siblings and reported eczema in child under study. 
Methods:  Information on family eczema-history was obtained from questionnaires completed 
at age 6 weeks and 1 year. When the children turned 2 years of age, a detailed questionnaire 
on health/different allergy related diseases was completed. Children with data at 6 weeks and 
2 years made up the 6-weeks cohort, whereas children with data at 1 year and 2 years 
comprised the 1-year cohort. Family eczema-history was divided into seven different groups; 
“eczema mother only”, “eczema father only”, “eczema sibling only”, “eczema mother and 
father, not sibling”, “eczema mother and sibling, not father”, “eczema father and sibling, not 
mother”, “eczema mother, father and sibling”.  “No family history of eczema” was set as 
reference group. 
Results: Some 13.7% and 14.2% of the girls, and 15.9% and 16.1% of the boys reported 
eczema at 2 years of age in the 6-week cohort (N = 2657) and in the 1-year cohort (N = 3087), 
respectively. Both maternal and paternal reports on eczema symptoms were significantly 
associated with eczema in child under study. Reporting family eczema-history at 1 year, 
"eczema sibling only" [adjusted odds ratio (aOR) = 3.13 (2.27-4.33)] as well as all other 
family-groups containing siblings with eczema were strongly associated with eczema 2 years. 
When family eczema-history was reported at 6 weeks, reporting of "eczema sibling only" was 
not associated to reported eczema at 2 years in index child [aOR = 1.31 (0.77-2.23)]. At 6 
weeks of age, some 6% of children under study had had their first symptoms of eczema, while 
80% of children had their first eczema-symptom by 1 year of age. 
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Conclusion: Both maternal and paternal history of eczema was associated with eczema in 
index child at 2 years of age. Having siblings with eczema strengthened the association 
between maternal and paternal reports of eczema with eczema in index child only when 
exposure was reported at 1 year. These findings indicate that results from questionnaires-
based studies on family eczema-history depend on whether or not index child has yet 
developed eczema. 
 
Review of paper III 
Early eczema and the risk of childhood asthma; a prospective, population-based study. 
Objective: To study the risk of current asthma and the co-existence of different allergy related 
diseases in 6 years old children with ever eczema reported at 2 years of age.  
Methods: Children included in the control cohort of the PACT study were included. 
Questionnaires on different environmental exposures and detailed information on the child’s 
health were answered at 2 years of age. An identical questionnaire on child’s health was 
completed at 6 years of age. Information on sensitization was obtained from the clinical 
investigation of a random subsample. Sensitization was defined positive if the child either had 
positive skin prick test or positive sIgE. Missing data were handled by multiple imputation 
analyses. 
Results: 2192 (46%) of included 2 years old children completed questionnaire at 6 years. The 
association between eczema at 2 years and current asthma at 6 years was aOR=1.80 (95% CI 
1.06-3.05). Four of ten children with eczema at 6 years had onset of eczema after the age of 2 
years, but co-existence of different allergy-related diseases at 6 years were higher among 
those with debut of eczema before 2 years of age. 
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Conclusion: Although most cases of early eczema in the general population are mild or 
moderate, they may involve an increased risk of developing asthma. Our findings support the 
hypothesis of an atopic march also in the general population. 
 
Review of paper IV 
Atopic dermatitis in adolescent boys is associated with greater psychological morbidity 
compared with girls the same age: the Young-HUNT study. 
Objective: To study self-reported mental distress in adolescents with eczema compared to 
healthy adolescents and adolescents with other chronic complaints such as headache, neck- or 
shoulder-pain, asthma, allergy and rhinitis.  
Methods: The young-HUNT 1 was conducted in 1995-97 as a cross-sectional survey among 
adolescents 13-19 years of age in Nord-Trøndelag County. All students were invited to attend. 
The participants completed questionnaires including information on somatic and mental 
health during one school hour.  
Results:  The participation rate was 89%. 8817 adolescents,13-19 years, (4433 boys) 
completed the questionnaires. The older teenagers of both sexes reported more symptoms of 
mental distress compared to the younger ones. Twice as many girls as boys reported eczema 
and except for rhinitis and allergy there was girl preponderance also in reported prevalence of 
other chronic complaints. Older female students with eczema reported more mental distress 
than younger ones. The association between headache and neck-/shoulder-pain and mental 
distress was significant in both sexes. The association between eczema and mental distress 
was stronger for boys (OR 2.1, 95% CI 1.6-2.9) than for girls (OR 1.3, 95% CI 1.1-1.6).  
Conclusion: There was a strong and consistent association between mental distress and 
eczema, headache and neck- or shoulder-pain for both sexes. However, for adolescents with 
51 
 
eczema, the association between symptoms and mental distress was stronger for boys than for 
girls.    
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DISCUSSION  
Methodological considerations 
The underlying premise in epidemiology is that disease, illness and ill health are not randomly 
distributed in the human population.7 When conducting an epidemiological study, both 
random as well as systematic errors may be afflictive.149 Random errors are variability in the 
data that reduce the precision of our estimates, whereas systematic errors in the study design 
or conduction of the study may lead to lack of validity.150, 151 Therefore, accuracy in 
estimation becomes an important goal.150  
 
Precision/Lack of random error 
Precision refers to the degree of variation in a measurement and can be increased in two 
different ways, either by increasing the size of the study, or by modifying the study design to 
obtain more precise information/measurements.150 Tests of statistical significance (p-values) 
are performed in order to evaluate whether the observed value, or a more extreme value, is 
caused by chance or not. When the p-value is ≤0.05, the probability of the observed result 
being that extreme solely by chance is 5% or less. The p-value is however not as informative 
as the confidence intervals (CI). Confidence intervals assess the extent to which the null-
hypothesis is compatible with the data and in addition provide an idea of the likely magnitude 
of the effect and the random variability of the point estimate.150 The width of a confidence 
interval depends on the amount of random variability, the precision, inherent in the data-
collection process. 
Both the Young-HUNT and the PACT study are comprehensive population-based studies, and 
throughout this thesis we have chosen to present test of significance as confidence intervals 
with level of significance set to 95%. In paper IV results were relatively precise, with narrow 
confidence intervals. In paper II and III, however, some exposure categories included few 
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participants. The estimates therefore were less precise. For example; when studying different 
family eczema-groups in paper II, there were too few participants in some of the groups to 
obtain precise estimates.   
 
Study design 
A cross-sectional study includes all persons or a representative sample of all such persons at 
the time of ascertainment. In cross-sectional studies both exposure and disease outcome are 
determined simultaneously for each individual, and the objective is limited to describing the 
population at that time. This type of design has limitations when it comes to establishing a 
temporal/causal relationship between exposure and outcome. It is however useful when 
studying associations. 
Cross-sectional data was used to study prevalence (paper I) and associations (paper IV).  
In paper II and III the design was that of a prospective cohort study. We identified the 
population under study at the beginning of the study, and during the follow-up time identified 
new cases of the disease under study. A major strength of this design is the possibility to 
study exposure before the outcome and thereby limiting the possibility of information-/recall 
bias. In paper II, we used information on family eczema-history (exposure) reported at two 
different times (6 weeks and 1 years), to study eczema in children (outcome). We found that 
information on exposure (eczema in siblings) reported at 6 weeks differed from information 
about the same exposure reported at 1 year. This finding confirmed the importance of 
measuring exposure (eczema in sibling) before the outcome is known (eczema in index child 
under study) in order to avoid recall bias.   
One limitation to the prospective design is the time aspect. If the disease under study has low 
incidence or takes several years to develop after exposure, the result may be a high number of 
non-responders/lost to follow-ups. The high number of lost to follow-up is a limitation in 
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paper III, where follow-up rate is only 46%. This low rate may lead to selection bias 
(discussed below). 
 
Validity/Lack of systematic error 
The validity of a study can be divided into two components; internal validity and external 
validity. Internal validity is the validity of the inferences as they pertain to the members of the 
source population, whereas external validity is the validity of the inferences as they pertain to 
the general population.150 Internal validity is therefore a prerequisite for external validity.   
Several types of bias can hamper internal validity. The most important ones are selection bias, 
information bias, and confounding. 
 
Internal validity 
-Selection bias 
Selection bias occurs when the association between exposure and disease are different for 
those who participate in the study and those who do not.149 
Participation rates in epidemiologic studies have declined during the last decades, and is of 
concerns to epidemiologists.152 Only 34% of eligible women were included in the intervention 
cohort of PACT, whereas the participation rate varied from 49% to 64% for the different age 
groups in the control cohort. Almost none of the participants made active withdrawal from 
any of the cohorts. The study is of long duration, and one can expect some degree of 
exhaustion among the health workers including participants to the study.152 The low inclusion 
rate is as reported by the health workers, due to low inclusion activity among GPs, health 
visitors and midwives, and not a consequence of self-selection among parents/children. This 
is affirmed in a non-responder study carried out, where 391 parents consecutively visiting 
maternal postnatal care were asked to complete a short, anonymous questionnaire on age, 
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socioeconomic status, allergic diseases in the family, smoking habits and participation in 
PACT. Only small and minor differences were found between participants and non-
participants in PACT.133  
If both participants and health workers forgot/failed to attend, we may assume that those lost 
to follow-up were lost at random. In both paper II and III we did a comparison of baseline 
characteristics between follow-ups and lost to follow-ups. Apart from more smoking mothers 
and fewer homeowners among the lost to follow-ups (indicating a certain socioeconomic 
gradient), insignificant differences were found between the two groups. This imply that 
despite no self-selection among participants in PACT, there is a socio-economic gradient 
among follow-ups compared to the lost to follow-ups. Several other studies have confirmed 
that persons with higher socioeconomic status are more likely to participate in scientific 
studies compared to those with lower socioeconomic status.153-155 Eczema has repeatedly been 
found more prevalent in higher socio-economic classes.156-158 Our reported prevalence of 
eczema and other allergy related disorders might therefore be too high.  
In the Young-HUNT 1, most of the non-participants were not in school the day of the survey. 
There is of course a possibility that the students not in school are those who suffer from the 
disease under study. However, if a larger number of the students had health problems, we 
would expect the associations found to be strengthened. 
 
-Information bias and misclassification 
In any cohort study it is important that the quality of the information obtained from the 
exposed is comparable and of equal quality as information obtained from the un-exposed. If 
this is not the case, a significant information bias and misclassification can be introduced. 
Misclassification is, by error, to assign a person/value into another category than what he/it 
should have been. Misclassification may occur in two forms; differential and non-differential.  
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Differential misclassification happens when either the exposure is misclassified differentially 
according to a person’s disease status or the disease is misclassified differentially according to 
a person’s exposure status. When having a differential misclassification, the effect we are 
studying can be either exaggerated or underestimated. 
 Non-differential misclassification results from the degree of inaccuracy that characterizes 
how information is obtained from any study group. When we have non-differential 
misclassification, the association tends to be diluted and shift the odds ratio towards 1.0. We 
are therefore less likely to detect an association even if there is one.   
Several of the variables used in the present studies are prone to misclassification. In paper I 
we validated the diagnosis AD by comparing the combination of a positive answer to two 
ISAAC questions against the UK working party’s diagnostic criteria and found the sensitivity 
and specificity to be 69.4% and 88.7% respectively. In other words; about 30% of those with 
AD are classified as false negative, whereas about 12% is classified as false positive. In using 
these two ISAAC questions in further studies in paper II and III, our OR estimates may be 
biased. However, since the misclassification is non-differential, our estimate most likely will 
tend to be diluted.  
Differential misclassification may occur as a result of recall bias. In the PACT study, parents 
who have allergic symptoms or children with allergic symptoms will be more aware of the 
same symptoms in the child under study, and therefore may tend to respond positively to 
questions on allergic symptoms compared to parents without allergic symptoms in the family. 
In paper II, where information on exposure is reported at two different ages of index child (6 
weeks and 1 year), the difference in reporting of eczema symptoms in siblings may be due to 
such misclassification.  
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Reported smoking habits may also be misclassified, as parents with asthmatic children will 
more likely under-report smoking. Participants in the intervention study were more aware of 
the study aim, and differential misclassification may have occurred (paper II). 
 
-Confounding 
A simple definition of confounding would be the mixing of effects.150 This implies that the 
effect of the exposure is mixed together with the effect of another variable, leading to bias.  
There are three criteria for a variable to be a confounder; 1) it must be a risk factor for the 
disease 2) it must be associated with the exposure under study in the source population and 3) 
it must not be affected by the exposure or by the disease, in particular not be an intermediate 
step in the causal pathway between exposure and disease.  
There are two principal ways of handling confounding in statistical analysis; by adjustment or 
by stratification.7 
In paper II, we studied the association between different family eczema-groups and eczema in 
index child 2 years of age. Potential confounding factors were identified by a priori 
knowledge, and in this paper we adjusted for sex, current smoking mother, age of mother at 
time of birth, keeping a dog and breastfeeding. In addition, we regarded socio-economic 
status as a potential confounder. This information was, however, missing in our data, so 
homeowner status was used as a proxy. Since we studied different family groups, 
breastfeeding is not an obvious confounder. Clearly, breastfeeding is not associated with 
eczema in father only. However, since four of the seven family groups included siblings, and 
breastfeeding is associated with eczema in siblings, we decided to include this as a potential 
confounder in the model.  
In paper III, we studied the association between ever eczema reported at 2 years of age and 
current asthma reported at age 6 years. The potential confounders were identified by a priori 
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knowledge, and in the final models, adjustments were made for sex, atopy in family, wheeze, 
smoking mother and sensitization. In addition, homeowner was used as a proxy for socio-
economic status.   
In paper IV we studied the association between atopic dermatitis (eczema) and mental 
distress. Due to interaction on the multiplicative level between sex and atopic dermatitis, we 
performed sex-stratified analyses. The stratified analyses were for headache, neck/shoulder-
pain, asthma, allergy, rhinitis and being healthy. One limitation to this model is the lack of 
adjustment for socio-economy. This information was not available in the Young-HUNT 1 
questionnaire, but could have been accounted for by merging the data with parental 
information on level of education. This was, however, not done.  
 
External validity/Generalizability 
External validity refers to the generalizability of the study.  
The PACT study was conducted in primary health care, and the participants were included 
consecutively. Although the study only included approximately 34% of eligible women in the 
intervention cohort and varied from 49-64% for the different age-groups in the control cohort, 
we claim that the study is a representative sample of women and children living in 
Trondheim. This is supported by the formerly described non-participant study. We have also 
compared data from PACT with data on all pregnant women in Trondheim from the Medical 
Birth Registry.159 No differences in the prevalence of smoking at the start of the pregnancy 
were found. There is no reason to believe that pregnant women in Trondheim differ from 
pregnant women in other large Norwegian cities, but this cannot be ruled out. The majority of 
the participants are Caucasians, and the results may not be generalized to other ethnic groups.  
In the Young-HUNT, the participation rate was high and invitations included the entire 
teenage population 13-19 years in the county. Nord-Trøndelag County has a slightly lower 
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level of education, income and lack of large cities compared to other Norwegian counties, but 
the population is stable and homogenous and considered representative for the total 
Norwegian population regarding industry, socio-economy, age-distribution, sex, mortality and 
morbidity.  
 
Strengths of the study 
The strength of the PACT study is the population based design, the inclusion of a large 
number of children and pregnant women from the general population, and the prospective 
design. A non-participant study confirms no selection bias among those included and those 
not included. Several of the questions used in the questionnaire have been tested regarding 
reliability, and questions on doctor-diagnosed asthma and symptoms of eczema showed very 
good/good agreement when compared to medical records.148 The questions on eczema were 
validated using the UKWP diagnostic criteria (paper I). 
The strength of the Young-HUNT 1 is the invitation to the entire adolescent population in 
Nord-Trøndelag County and the high participation rate.  
 
Limitations of the study 
Although we believe that the participants of PACT (with the limitations of socio-economy 
already mentioned) are representative of the general population, the low participation and 
follow-up rate is a limitation of the study. Self-reported data may also be a limitation, 
especially in the intervention cohort where the participants knew the study aim.  
In the Young-HUNT 1, self-reported data may be a limitation. It is also possible that non-
responders were absent from school due to more frequent illness/disease.    
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General discussion 
Prevalence and severity of eczema in 2-years old children 
Prevalence is the most common measure of disease frequency in epidemiology, and provides 
important information about the burden of disease in a population.25 Prevalence can be 
measured as point prevalence or period prevalence. Suggestions have been made to use one-
year period prevalence for comparative purposes, as this will take into consideration the 
relapsing nature of the disease and at the same time minimizing recall bias.25  Prevalence of 
(atopic) eczema has been widely studied in 6-7 years old and 13-14 years old children through 
the ISAAC studies.111 Among children 2 years of age, however, prevalence studies have been 
scarce.25  In paper I we estimated the prevalence of eczema both based on reported symptoms 
in questionnaires and based on the UKWP criteria after clinical examination of a random 
subsample. In the subsample the prevalence obtained from questionnaires was 20.6% whereas 
the prevalence according to the U.K. criteria was 15.9%. This might reflect the fact that the 
prevalence measures are different; the prevalence in the questionnaire is a cumulative 
prevalence, whereas the prevalence according to the UKWP criteria is a one-year period 
prevalence. Otherwise, the reported prevalence from the questionnaire represents an over-
reporting or a selection bias.  
Severity outcome measures in eczema are useful for several reasons. In epidemiological 
studies severity of disease together with prevalence is helpful in estimating the disease burden 
in a community. In a systematic review of randomized controlled trials of therapeutic 
interventions for eczema, the investigators found that only 27% of the trials used an objective 
assessment of eczema severity used before.160 In clinical practice severity grading is also a 
useful tool, but in order to be able to translate trial evidence into clinical practice the same 
outcome measures as in eczema trials should be used.98 Also, outcome measures should be 
considered important both for researchers, patients and clinicians. As for diagnostic criteria, 
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outcome measures should also be standardized. This will help to reduce bias from selective 
outcome reporting, and facilitate the possibility of performing meta-analyses.98, 161 The 
Harmonizing Outcome Measurements in Eczema (HOME) is yet to be agreed upon.  In paper 
I we used both SCORAD and NESS as outcome measures. In a review article evaluating 20 
different outcome measures, SCORAD was one of three measures recommended used in 
future studies.94 For NESS the validity criteria were not fully met, but appeared to be 
acceptable until further validation studies are available. Compared to SCORAD, NESS is easy 
to use, and grades the severity into mild, moderate or severe. We found only 3/59 children to 
have severe disease when measured by NESS whereas none had severe disease according to 
SCORAD. This is reassuring, and strengthens our conclusion that most children in the general 
population have mild or moderate disease. We did, however, only investigate the children 
once, and the fluctuation in symptoms could therefore not be captured.     
 
Family eczema history 
Several studies on family eczema history have concluded that there seem to be a maternal line 
of inheritance regarding AD.45-47, 162 Concerning allergic diseases, several factors such as 
maternal diet, microbial exposure and smoking have been shown to modify disease risk, some 
through possible epigenetic changes.68, 163-165 Underlying mechanisms for this observation 
could be shared environment by mother and child such as gene-environment interactions 
operating in utero, breastfeeding, or parent-specific gene expression (genomic imprinting). 
Genomic imprinting implies that expression of the genetic information is modified according 
to whether it is passed to the child via the egg or the sperm.48 In addition, as illustrated in 
Fig.5, both pre-and post-natal environment may also alter the modulation of gene expression. 
63 
 
 
 
 
 
 
 
Disease prevention through environmental strategies that can re-programme gene expression 
and thereby disease phenotype and disease predisposition through epigenetic mechanisms 
should be addressed in future studies.166 
In paper II we did not find support for a maternal line of inheritance, but in line with other 
studies found that both a paternal and a maternal history of atopy were associated with 
increased risk of eczema in the offspring under study.43, 48, 61, 167 As discussed in paper II, this 
may be due to bias in reporting of paternal symptoms by mothers filling in the questionnaires. 
Another possibility is that the lack of a maternal line of inheritance might be due to different 
phenotypes of eczema being studied. We studied eczema, and sensitization in both parents 
Figure 5. A range of factors in the prenatal and postnatal environment have the 
capacity to alter epigenetic programming and gene expression during early 
development. (Copyright 2010 Wiley. Used with permission from Martino DJ and 
Prescott SL. Silent mysteries: epigenetic paradigms could hold the key to conquering the 
epidemic of allergy and immune disease. Allergy 2010 Jan;65(1):7-15. John Wiley and 
Sons) 
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and offspring was unknown. In one study reporting a maternal line of inheritance, 
hospitalized children were included.47 It is reasonable to assume that hospitalized children 
with eczema more often are sensitized and have a more severe form of eczema than those not 
hospitalized. However, another study found no differences regarding parental inheritance 
when sensitized children were compared with non-sensitized children.61 This study was, 
however, performed on older children. These findings emphasize the importance of a strict 
disease definition in order to compare studies. Also, age of child and type of sensitization 
should be taken into consideration.  
 
The atopic march 
In paper III we studied the atopic march, and found an increased risk of asthma at 6 years of 
age among children with eczema at 2 years of age compared to children without eczema at 2 
years. Whether or not there is an atopic march is debated.117, 122 If eczema is a risk factor for 
subsequent asthma, the explanations could be that this is caused either by 1) a defect skin 
barrier function with subsequent sensitization, 2) an immunologic dysregulation,  3) shared 
environmental factors that predisposes for both eczema and asthma  or 4) a complex 
combination of all these factors. Genome screens for AD and asthma have not shown any 
clear overlap in the chromosomal regions, indicating that susceptibility to these diseases are 
mediated through different genes.168 On the other hand, association studies on FLG and 
eczema are strong and robust, and loss-of-function mutations in this gene confer increased 
risk for both eczema and eczema in combination with asthma.12, 169 In a population-based 
study from the U.K., support is given to the findings of distinct phenotypes of eczema rather 
than a progression of related disorders.170 However, risk of asthma was not limited to those 
with atopic sensitization, and the authors indicate that a possible mechanism could be priming 
of a Th-2 phenotype, caused by systemic effects of early eczema, which influence airway 
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responsiveness and has effects in later childhood. Our finding in paper III confirms that 
eczema is an individual risk factor for asthma regardless of sensitization. The Early Treatment 
of the Atopic Child (ETAC) study group is an international double-blind placebo-controlled 
randomized trial aiming at preventing the progression from eczema to asthma by means of 
administrating cetirizine.171 At 3 years of age, asthma was delayed, and in some cases 
prevented, in a subgroup of patients with atopic dermatitis sensitized to grass pollen. The 
overall risk for eczematous children to develop asthma was, however, not reduced. Several 
authors have argued that restoring the skin barrier could prevent both eczema severity and 
progression form eczema to asthma.115, 121, 122  If the link between eczema and asthma is 
causal, treatment of the eczema may lead to a reduction in incident cases of asthma.121 The 
eczema treatment would include not only moisturizers containing ceramides, free fatty acids 
and cholesterols, but also topical treatment that reduce the skin inflammation. Thereby, both 
restoration of the skin barrier and treatment of the skin inflammation are taken care of. This 
might inhibit the systemic effects of eczema and possibly the airway responsiveness. 
Intervention studies are needed in order to confirm or refute this possible causation.121         
 
Mental distress in adolescents with eczema 
In order to manage the treatment of chronic skin diseases it is important to recognize the 
impact these diseases have on quality of life and mental health both in those affected by the 
disease and their families/caretakers. Eczema is a pruritic disease, and several investigators 
have showed an association between itch/pruritus and mental distress/psychosocial 
morbidity.172, 173 Some have also addressed this problem among adolescents.174 Mental health 
problems such as symptoms of depression and anxiety increase in prevalence throughout 
adolescence, and girls are more often affected than boys.175, 176 Also, adolescents with chronic 
diseases have more depressive symptoms than healthy young people.177 In paper IV we have 
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addressed the association between mental distress and atopic dermatitis among adolescents, 
and found that the association was stronger for boys than for girls.  
A birth cohort from the U.K. following children up to the age of 18 years found the 12-month 
prevalence of eczema at age 18 years to be 16.3% in girls and 8.3% in boys. At age 4-10 and 
earlier, no significant difference in the prevalence among the sexes were observed. The 
female predominance at age 18 years was due to more girls developing non-atopic eczema, 
whereas more boys had outgrown their eczema.178 Severity of eczema is correlated to serum 
IgE levels, and children with severe AD have increased risk of sensitization to food- and aero-
allergens.179 With this in mind, it is reasonable to hypothesize that adolescent boys may have 
more severe eczema than girls. Another possibility is that boys with eczema are less likely to 
treat their skin disease, and therefore have more itch and nuisance related to their eczema than 
girls.180 Whether the eczema leads to mental distress or mental distress leads to deterioration 
of eczema cannot be distinguished from our study. In treating young people with eczema it is, 
however, important to remember the association between mental distress and eczema, and, if 
possible, pay extra attention to the boys.   
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CONCLUSIONS 
1) Close to every fifth child in Trondheim have had eczema by the age of 2 years. It is 
one of the most common diseases of childhood, and therefore represents a challenge 
for health personal concerning advice given both related to treatment and prevention. 
Fortunately, more than two thirds of the cases had mild degree of disease.    
 
2) A maternal line of inheritance was not confirmed in this study. Information on family 
eczema history should be collected as early as possible and preferably before the child 
develops eczema in order to avoid recall bias. 
 
3) Despite the fact that most children with eczema have mild or moderate degree of 
disease, having eczema at age 2 years increased the risk of asthma at 6 years of age 
when comparing to those without eczema at 2 years of age. This finding confirms the 
hypothesis of an atopic march also in a general population. 
 
4) Eczema as well as other chronic complaints was associated with mental distress 
among adolescents 13-19 years. The association between eczema and mental distress 
was, however, stronger for boys than girls.  
 
 
Uniform diagnostic criteria and outcome measure are of crucial importance in future studies 
of eczema.  
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FUTURE PERSPECTIVES 
The PACT study is comprehensive, and unique in its kind in Norway. One of the main points 
in further research will be to investigate if the intervention has led to a decrease in incident 
cases of allergy related disorders at 6 years.  Two sub-studies have been conducted within the 
frames of the PACT study, the IMPACT study and the ProPACT study. These sub-studies 
have collected biological material, and a large biobank has been stored. Collaboration with 
the Norwegian University of Life Sciences in Ås has already been established, and further 
studies on gut microbiota composition and microbial composition/cytokine profile in breast-
milk will be conducted.  
Collaboration with the Instituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, has 
also been established. Together with Institut National de la Santé et de la Recherche Médicale 
(INSERM) Paris, France, they conduct the project “The Hygiene Hypothesis: Revisiting the 
Concept by Integrating Epidemiology and Mechanistic Studies”. This project is granted 
funding by the European Research Council. Since the Italian arm of this study use 
questionnaires very similar to the questionnaires used in the PACT, pooling of data is 
possible. Direct and indirect markers related to the hygiene hypothesis will be explored in 
both PACT and the Italian dataset. This work has started.       
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Abstract
Background: A maternal line of inheritance regarding eczema has been described in several studies, whereas
others find associations to both a maternal as well as a paternal line of inheritance. When studying family history
of eczema symptoms, cohort studies including siblings are rare. Time point for assessing family eczema-history
could be of importance when studying the associations between family eczema-history and children with eczema,
as parents with unaffected children may not recall mild symptoms in other siblings or their own disease history.
We therefore aimed to study the associations between reported eczema in mother, father and siblings and
reported eczema in index child where information on family history was collected at two different ages of index
child.
Methods: Parents/children participating in The Prevention of Allergy among Children in Trondheim (PACT) study
were given questionnaires on reported eczema symptoms in mother, father and siblings at 6 weeks and 1 year.
When index child was 2 years of age, a detailed questionnaire on different health issues with emphasize on
different allergy related disorders were filled in.
Results: Both maternal and paternal reports on eczema were significantly associated with eczema in index child.
Reporting family eczema-history at 1 year (N = 3087), “eczema sibling only” [adjusted odds ratio (aOR) = 3.13 (2.27-
4.33)] as well as all other family-groups containing siblings with eczema were strongly associated with eczema 2
years. When family eczema-history was reported at 6 weeks (N = 2657), reporting of “eczema sibling only” was not
associated to reported eczema at 2 years in index child [aOR = 1.31 (0.77-2.23)].
Conclusions: Having sibling(s) with eczema strengthened the associations between maternal and paternal reports
on eczema with eczema in index child only when exposure was reported at 1 year. These findings indicate that
results from questionnaires-based studies of family eczema-history depend on whether or not index child has yet
developed eczema.
Trial registration: ISRCTN: ISRCTN28090297
Background
Atopic eczema is a complex disease caused by a mainly
unknown interaction between genetic and environmen-
tal factors [1]. The genetic component of the disease has
been demonstrated in twin studies [2], and several stu-
dies have emphasized the association of atopy in the
mother with the development of atopic eczema in the
child whereas the evidence for association to an atopic
father has been somewhat weaker [3-6]. In the last
years, however, other studies have concluded that the
association with both paternal as well as maternal atopy
is important in the development of allergic disease in
the offspring [7-10] Several candidate genes linked to
the development of eczema have been identified [11],
but so far only mutations in the gene encoding filaggrin
(FLG) have been widely replicated [12].
When family eczema-history is studied, several investi-
gators have studied the protective effect of having a high
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number of siblings on the development of allergic dis-
eases [13,14]. However, few prospective studies from the
general population have addressed the association
between allergy related disorders in older siblings and
the child under study [4,15].
When studying diseases in the general population,
self-reported questionnaires are often used. One of the
flaws with such information could be recall bias con-
cerning how well adults remember both their own child-
hood diseases as well as diseases in children with mild
symptoms [16-18].
The aim of this prospective study was therefore to
investigate the associations between reported eczema in
mother, father and siblings and reported eczema in
index child at 2 years of age where family eczema-his-
tory as well as exposure was collected at two different
ages of the index child.
Methods
The Prevention of Allergy among Children in Trond-
heim (PACT) study is a large population- based pro-
spective study on allergy related disorders conducted in
Trondheim, central Norway. Trondheim has approxi-
mately 165 000 inhabitants and 2100 deliveries pr year.
From September 2000 all pregnant women as well as
children 6 weeks, 1 year, and 2 years of age visiting
their general practitioner or community based midwife
were consecutively invited to attend the study. Women/
parents were eligible to participate if they were able to
complete a questionnaire in Norwegian. Recruitment of
6 weeks old, 1 year and 2 years old children closed June
30th 2006. The PACT-study is described in further detail
elsewhere [19].
-Study design
Family eczema-history and exposure variables was
assessed from questionnaires when the child was 6
weeks old (Q2) and 1 year old (Q3) [19]. When the
child was approximately 2 years of age, the parents
answered a questionnaire on the child’s health (Q5).
The questionnaires Q2 and Q3 included questions on
different allergic diseases in parents/siblings (including
family eczema-history) as well as on indoor climate,
infections, medication, vaccines, day-care, exposure to
nicotine, pets, breastfeeding and diet. Q5 included ques-
tions on different health issues in index child with
emphasize on allergy related disorders. The latter ques-
tions were adopted from the International Study of
Asthma and Allergies in Childhood (ISAAC) protocol
and modified to fit the actual age group [20].
By March 2009 some 2657 parents (54.6%) had com-
pleted Q2 as well as the child’s health-questionnaire at
the age of 2 years (Q5), and these are included in the
6 weeks cohort. The 1 year cohort comprises 3087
parents (60%) who had completed Q3 together with
Q5 (table 1).
These two cohorts (6 weeks, N = 2657 and 1 year, N
= 3087) were used to prospectively study reported
family eczema-history and association to eczema in
index child reported at 2 year.
-Study variables
-The outcome variable studied was ever eczema reported
at the age of 2 years (Q5). The index child was defined
as having eczema if both questions “Has your child ever
had eczema?” and “Has your child ever had an itchy
rash which was coming and going for at least 6
months?” were answered positively [21].
Family eczema-history and exposure variables were
assessed in Q2 and Q3.
-Family eczema- history
Eczema in mother, father or sibling was defined as “yes”
if any one of the questions “have you, the child’s father
or any of your joint children ever had eczema” or “have
you, the child’s father or any of your joint children had
eczema or used medication against eczema during the
last 12 months” were ticked “yes” for mother, father or
sibling.
The reporting of family eczema history was then cate-
gorized into the seven different family eczema groups
possible; “mother only”, “father only”, “sibling only”,
“mother and father”, “mother and sibling”, “father and
sibling”, “mother, father and sibling”.
-Exposure variables
The term “breastfeeding now” was used regardless of
whether or not solid food or formulas was given to the
child in addition to breast milk.
“Current smoking mother” was regarded as “yes” when
the question “do you smoke now?” was answered
positively.
Maternal and paternal level of education was not
accounted for in the original questionnaire. Thus, home-
owner status from the questionnaire was used as a
proxy for socioeconomic status.
“Dampness” was defined “yes” when the sum of 8 dif-
ferent questions concerning damp/mould at home was 3
or more.
-Ethics
All parents signed a written consent form to participate
in the PACT study. The study was approved by the
Regional Committee for Medical Research Ethics and
the Norwegian data Inspectorate Board (Ref 120-2000)
(Ref 2003/953-3 KBE/-).
-Statistics
Univariate associations between eczema in index child
and different family eczema-groups as well as the
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different exposure variables were analysed using simple
logistic regression.
Associations adjusted for potential confounders were
obtained by logistic regression models. Maternal age
was used as a linear variable in the regression analysis.
All other explanatory variables were either dichotomized
or categorized. Dummy variables were made when the
independent variables contained more than two cate-
gories. Family eczema-groups were also categorized, and
those with no family history of eczema (mother, father
or sibling) were set as reference group.
The logistic regression models were adjusted for con-
founding factors identified by a priori knowledge to the
problem being studied. In the final multivariable regres-
sion analysis, adjustments were made for gender, home-
owner, current smoking mother, breastfeeding, keeping
a dog and age of mother at the time of birth.
A separate model was made for older siblings with
and without eczema. In addition to adjustment for the a
priori defined confounding factors, adjustment was
made for eczema mother and eczema father. Interaction
between eczema mother and eczema father was tested.
In the multivariable analysis the number of missing var-
ied for each variable under study, but never exceeded 9%.
Unadjusted and adjusted associations are presented as
odds ratios (OR, aOR). 95% confidence intervals (CI)
were estimated for binominal distributed data.
Statistical Package for Social Science version 15.0
(SPSS inc., Chicago; IL, USA.) and STATA version 11.2
for Windows (STATA Corporation, College Station, TX,
USA) were used for the analyses.
Results
Some 13.7% and 14.2% of the girls, and 15.9% and 16.1%
of the boys reported eczema at 2 years of age in the 6-
week cohort (N = 2657) and in the 1-year cohort (N =
3087), respectively.
When exposure was reported at 6 weeks, only some
6% of the index children with eczema had had their first
symptoms of eczema, whereas the corresponding num-
ber was about 80% among those who reported exposure
at 1 year.
Some 77% of children in the 6-week cohort also
attended the 1-year cohort. Between 6 weeks and 1 year,
some 9.6% of these parents changed their answer from
“no” to “yes” regarding whether or not the index child
had a sibling with eczema or not. Among those with
eczema in index child reported at 2 years, some 28.5%
changed their answer from “no” to “yes” from 6 weeks
to 1 year, as opposed to some 6.4% among those with-
out eczema in index child 2 years (data not shown).
In univariate analyses, keeping a dog was the only sta-
tistically significant environmental factor associated with
reported eczema at 2 years of age in both cohorts.
Table 1 Characteristics of the two study populations with exposure reported at 6 weeks and 1 year
Exposure reported at 6 weeks, N = 2657 Exposure reported at 1 year, N = 3087
Reported exposure a n % (95% CI) n % 95% CI
Gender Male 1333 50.2 (48.3-52.1) 1529 49.5 (47.8-51.3)
Homeowner Yes 2242 84.4 (82.9-85.7) 2680 86.8 (85.6-88.0)
Cat Yes 239 9.0 (7.9-10.1) 266 8.6 (7.7-9.7)
Dog Yes 247 9.3 (8.2-10.5) 249 8.1 (7.1-9.1)
Bird Yes 63 2.4 (1.8-3.0) 70 2.3 (1.8-2.9)
Dampness Yes 105 4.0 (3.2-4.8) 117 3.8 (3.1-4.5)
Maternal current smoking Yes 189 7.1 (6.2-8.2) 453 14.7 (13.4-16.0)
Paternal current smoking Yes 399 15.0 (13.7-16.4) 499 16.2 (14.9-17.5)
Premature birth, < 37 weeks Yes 75 2.8 (2.2-3.5) 75 2.4 (1.9-3.0)
Birth-weight <2500gr 74 2.8 (2.2-3.5) 105 3.4 (2.8-4.1)
2500-3999gr 1937 72.9 (71.2-74.6) 2196 71.1 (69.5-72.7)
≥4000gr 623 23.4 (21.8-25.1) 691 22.4 (20.9-23.9)
Breastfeeding now Yes 2481 93.4 (92.4-94.3) 1114 36.1 (34.4-37.8)
Number of siblings 0 1172 44.1 (42.2-46.0) 1343 43.5 (41.7-45.3)
1 920 34.6 (32.8-36.5) 1033 33.5 (31.8-35.2)
2 or more 533 20.1 (18.6-21.6) 711 23.0 (21.6-24.6)
Any kind of infection, child Yes 903 34.0 (32.2-35.8) 2983 96.6 (95.9-97.2)
Antibiotics ever, child Yes 58 2.2 (1.7-2.8) 706 22.9 (21.4-24.4)
mean range SD mean range SD
Maternal age 30.1 17-48 4.49 29.98 17-48 4.46
a Number of missing varies
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When reporting family history at 6 weeks, the associa-
tion between eczema in index child at 2 years and dif-
ferent eczema- groups containing only one or both of
the parents, both “eczema mother only” and eczema
father only” were statistically significant in the univariate
analyses [(OR, 1.61; 95% CI 1.18-2.21), (OR, 1.69; 95%
CI 1.16-2.46)] (table 2). When adding reporting of
eczema in a sibling to eczema in one or both of the par-
ents, we found “eczema mother and sibling, not father”
and “eczema mother, father and sibling” to be signifi-
cantly associated with eczema in the index child at 2
years [(OR, 3.41; 95% CI 1.91-6.10) and (OR, 3.15; 95%
CI 1.42-7.02)].
Corresponding univariate analyses of different family
history eczema-groups reported at 1-year showed no dif-
ferences in associations with eczema in index child at 2
years for any of the groups containing one or both of
the parents without a sibling compared to 6 weeks. For
all groups including eczema in siblings there were a
consistent and highly significantly association with
eczema at 2 year in the index child (table 2).
In the adjusted model, we found a significant associa-
tion between “eczema mother only” and “eczema father
only” reported at 6 weeks and eczema in the index child
at 2 years [(aOR, 1.57; 95% CI 1.13-2.18), (aOR, 1.73; 95%
CI 1.18-2.55)] (table 3). No association was found with
“eczema sibling only” (aOR, 1.31; 95% CI 0.77-2.23).
When adapting the same model on reported eczema
in mother, father and sibling at 1 year, we found a sig-
nificant association with eczema at 2 years in all groups
but “eczema mother and father” (Table 3). As opposed
to the family eczema-history reported at 6 weeks, a sig-
nificant association was observed for “eczema sibling
only” (aOR, 3.13; 95% CI 2.27-4.33). Adding eczema in
sibling to either of the eczema parent groups signifi-
cantly strengthened the associations in the 1 year
cohort; “eczema mother and sibling, not father” (aOR,
4.48; 95% CI 2.96-6.78), “eczema father and sibling, not
mother” (aOR, 5.43; 95% CI 3.27-9.02).
In the model testing association between siblings with
and without eczema and association to eczema in index
child 2 years, we found a significant association for sib-
lings with eczema in the 1 year cohort only (aOR, 2.18;
95% CI 1.63-2.92). No interaction between eczema
mother and father was found in either of the cohorts (p
for interaction = 0.48 at 6 weeks, p for interaction =
0.10 at 1 year) (data not shown).
Table 2 Univariate association between different family eczema-groups and eczema 2 years
Proportion of children with
eczema 2 years
OR (95%
CI)
Proportion of children with
eczema 2 years
OR (95%
CI)
Reported 6 weeks Reported at 1 year
No family eczema a 12.5% (217/1738) 1.0 No family eczema a 10.7% (201/1885) 1.0
Eczema mother only 18.7% (61/326) 1.61
(1.18-2.21)
Eczema mother only 16.7% (59/354) 1.68 (1.22-
2.30)
Eczema father only 19.4% (39/201) 1.69
(1.16-2.46)
Eczema father only 18.1% (39/215) 1.86 (1.27-
2.71)
Eczema mother and father,
not sibling(s)
19.7% (13/66) 1.72
(0.92-3.21)
Eczema mother and father,
not sibling(s)
16.0% (12/75) 1.60 (0.85-
3.01)
Eczema sibling(s) only 16.9% (22/130) 1.43
(0.88-2.31)
Eczema sibling(s) only 25.5% (67/263) 2.86 (2.09-
3.92)
Eczema mother and sibling
(s), not father
24.1% (19/79) 3.41
(1.91-6.10)
Eczema mother and sibling
(s), not father
33.9% (42/124) 4.29 (2.88-
6.40)
Eczema father and sibling
(s), not mother
23.1% (9/39) 2.10
(0.99-4.49)
Eczema father and sibling
(s), not mother
37.5% (27/72) 5.03 (3.05-
8.28)
Eczema mother, father and
sibling(s)
31.0% (9/29) 3.15
(1.42-7.02)
Eczema mother, father and
sibling(s)
40.0% (14/35) 5.59 (2.80-
11.16)
a No family eczema is the reference point for all other family eczema-groups
Table 3 Adjusted association between different family
eczema-groups and eczema 2 years a,b
Reported at 6
weeks
Reported at 1
year
aOR (95% CI) aOR (95% CI)
Eczema mother only 1.57 (1.14-
2.18)
1.62 (1.17-2.24)
Eczema father only 1.73 (1.18-
2.55)
1.98 (1.35-2.90)
Eczema mother and father, not
sibling
1.83 (0.97-
3.42)
1.73 (0.91-3.28)
Eczema sibling only 1.31 (0.77-
2.23)
3.13 (2.27-4.33)
Eczema mother and sibling, not
father
2.59 (1.34-
5.00)
4.48 (2.96-6.78)
Eczema father and sibling, not
mother
2.14 (0.99-
4.63)
5.43 (3.27-9.02)
Eczema mother, father and sibling 3.78 (1.66-
8.63)
6.25 (3.09-
12.65)
a ) No family eczema is the reference point for all other family eczema-groups
b ) Model adjusted for gender, homeowner, current smoking mother,
breastfeeding, keeping a dog and age of mother at time of birth.
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Discussion
In this large population based study with reports of
family eczema-history at two different points of time, we
found that having either parent with eczema was signifi-
cantly associated with reported eczema at the age of 2
years. The associations were consistent when reported
at 6-weeks as well as 1 year. Having one or several sib-
lings with eczema, with or without either of the parents
with eczema reported at 1 year, was also strongly asso-
ciated with reported eczema at 2 years and significantly
stronger for siblings only.
We have data on exposure reported at 6 weeks and 1
year. Although the reporting of exposure was at two dif-
ferent points of time, the two cohorts are comparable.
Some 77% of those who answered Q2 (6 weeks) also
answered Q3 (1 year) as well as Q5 (2 years). The two
cohorts are generated from the same geographic area
(the city of Trondheim), during the same time-period,
and by the same midwifes and GPs.
Although eczema is a relatively prevalent disease
among children in the western world, most children have
mild degree of disease, making the diagnosis and differ-
entiating between different phenotypes of the disease as
well as mild cases challenging [21-23]. We found the pre-
valence of reported eczema 2 years to about 15% both
among those who reported the family eczema history at
6-week and those who reported at 1 year, indicating a
high reliability of the questions. Any misclassification of
eczema cases might therefore be non-differential, and if
so may have diluted the associations.
Several studies describe a maternal line of inheritance
concerning eczema [5,6,22]. This maternal line of inheri-
tance has led investigators to hypothesize that environ-
mental influences operating in utero or in early infancy
may be essential in determining disease expression [24].
In this study eczema in the index child was significantly
associated with eczema in mothers as well as fathers.
This finding is in accordance with several others [8,9,25]
and not supportive to the hypothesis of paternal geno-
mic imprinting. However, parental recall bias should be
taken into consideration also here. Any one parent who
followed the child was asked to participate in the
PACT-study. One limitation in this study is the fact that
we don’t know which parent filled in the questionnaire.
Since many of the women were included during preg-
nancy and during their child’s first year of living, we
assume that mothers most likely have accepted to parti-
cipate in the study when visiting her GP or midwife. It
is therefore most likely that mothers have filled in the
questionnaires. In both cohorts more boys than girls
reported eczema at age 2 years. Despite this, more
mothers than fathers reported to have ever eczema.
When studying recall bias in parental questioning, a
German group found that mothers tended to report
more atopic diseases in a second questionnaire than in
the first, whilst fathers were influenced by their child’s
development of atopic disease [16]. In families without
childhood eczema the sensitivity for mothers reporting
paternal eczema was lower than in families with at least
one child with eczema. The specificity was about the
same [26]. Although effect size is small in a population
setting, filaggrin haploinsufficiency is a highly penetrant
trait, and associated with increased eczema severity [27].
It is therefore likely that severe eczema in any one of
the parents represent a greater risk of eczema in the off-
spring. It seems also likely, that mothers more often
would report a positive paternal history of eczema if the
disease was severe or persisted into adulthood. The lat-
ter is supported by a Swedish study, who found that
recall of childhood eczema history among adults was
influenced by several factors such as high prevalence of
eczema after the age of 15, more visits to the physician
after the age of 15, more hand eczema and more sick-
leave due to eczema [17]. Since mothers most likely
have filled in our questionnaires, an overestimation of
the association between paternal eczema and eczema in
index child is possible. This might be due either to
more severe eczema in fathers or increased awareness
due to development of eczema in one of the children.
Both could explain the lack of a maternal line of inheri-
tance in this study.
When family history of eczema is studied, allergy
related disorders in siblings are seldom accounted for in
the risk analysis. We found that, although having any
one parent with eczema was associated with eczema in
index child at 2 years, having one or several siblings
with eczema together with mother and/or father with
eczema was strongly associated with eczema in index
child 2 years when reports were collected at 1 year. This
association was also seen when eczema was reported
only in sibling(s). There are different interpretations of
these findings. One possible explanation could be that
this is a reflection of a parental genetic disposition with
incomplete penetrance [4]. Mutations in the gene
encoding filaggrin (FLG) have been identified as a strong
predisposing factors for eczema [28] and especially
severe phenotypes of the disease [29], but other candi-
date genes are also under investigation [11]. Different
environmental factors can alter the expression of differ-
ent genes, as have been showed with the exposure to cat
within the first year of life in those who carry mutations
of FLG [30]. Other environmental factors such as early
colonisation from maternal microbial flora as well as
shared environment among siblings with the same
genetic predisposition may act in a similar way and
explain the “eczema-sibling-effect” in this study.
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The “eczema-sibling-effect” was not significant when
reported at 6 weeks. Awareness of disease in first child
with mild disease might be absent until same kinds of
symptoms as e.g. dry skin is observed in second child.
Also, in mild cases of eczema a significant proportion of
the children are disease free by the age of 3 years [31].
In this study, some 28.5% of parents with eczema in
index child at 2 years changed their answer from “no”
when reported at 6 weeks to “yes” when reported at 1
year regarding the question on whether or not siblings
had eczema, as opposed to 6.4% among those without
eczema in index child. These findings could be inter-
preted as an increase in awareness since some 80% of
index children had developed symptoms on eczema at
age 1 year. Another interpretation is that some of the
older siblings have not yet been diagnosed with eczema.
This is however less likely, since a majority of children
with eczema starts with their disease during their first
year of life [31].
In a German study of children 9-11 years old having
two first degree relatives with the same atopic disease
was highly associated with eczema [4]. Diepgen & Blett-
ner found a stronger correlation between siblings than
between siblings and parents for all atopic diseases, also
atopic dermatitis [5]. Eczema in an older sibling was
also found to be an independent risk factor for eczema
among 4-years old in Sweden [9].
When only some 60% of those finishing the question-
naires on exposure were answering the questionnaires
on health, one could argue that the data are prone to
self-selection. In both cohorts the lost-to-follow-up
group contained more current smoking mothers and
fewer homeowners, indicating a lower socio-economic
status (data not shown). However, other exposure data,
including reported family eczema-history did not differ
among those who followed up and those who did not.
Another limitation of the study was the reporting
eczema in parents and siblings without a clinical verifi-
cation. The question “have you, the child’s father or any
of your joint children ever had eczema” is a core ISAAC
questions, but is most often used in combination with a
question on rash located in typical places or diagnosis
verified by a doctor. To the best of our knowledge, the
question has not been validated in an adult population.
However, the almost similar phrasing “have you ever
had childhood eczema” was validated among adults in a
Swedish population. The sensitivity and specificity of
this question was 89.9% and 70.7%, respectively [32],
and an overestimation of the reported prevalence of
childhood eczema among adults is therefore likely.
Regarding the use of this question among children (sib-
lings), we have validated this in a former publication
[21]. This question alone, without a question identifying
rash on typical location, gave a sensitivity of 96.8% and
a specificity of 68.0% when validated against the UK
Working Party Criteria. Adding a question of rash on
typical locations decreased the sensitivity whereas the
specificity increased. This gives reason to believe, that
there might be an overestimation of reported eczema
among the siblings, since other forms of dermatitis in
young children, such as seborrhoeic dermatitis as well
as nappy dermatitis might have been included. However,
in case of such a misclassification, there is no reason to
believe that this has changed from 6 weeks to 1 year,
and could therefore not explain the differences in
reporting of eczema in siblings in the two cohorts.
The strengths of this study are the large number of
unselected participants as well as the prospective design.
The consistency of reported eczema indicates a high
reliability of the questions and the prevalence of
reported eczema is well in line with the prevalence
found in the PACT endpoint-study [21]. In addition, the
focus is on eczema-groups only, since other studies have
showed that parental eczema may be a better marker
for eczema in the offspring than other parental atopic
diseases [8,33].
Conclusions
We found that reporting having a sibling with eczema at
1 year was significantly associated with reported eczema
at 2 years. Eczema in mother as well as eczema in father
was both associated with eczema 2 years. When family
eczema-history was reported when index child was 1
years of age, the associations with eczema 2 years were
significantly stronger for both parents if sibling(s) of the
index child had eczema, and association was signifi-
cantly stronger for sibling(s) reported at 1 year com-
pared to 6 weeks. However, although siblings had
eczema, the shared environment by mother and child
did not result in any difference between maternal and
paternal associations to eczema 2 years in index child.
The finding of different associations when family-
eczema history was reported at 6 weeks compared to
when family eczema-history was reported at 1 year indi-
cate bias in information gathering and has important
implications on comparability of studies measuring the
effect of older sibling disease on index child`s risk of
eczema.
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